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Abstract 
Since living conditions have improved and antibiotics have entered routine use, 
valvular heart disease (VHD) in the developed world is mostly degenerative in 
origin, rather than rheumatic. Our population is increasing with age, and therefore the 
burden of VHD is likely to increase. Despite this, the epidemiology & 
prognostication in VHD remain poorly understood. A better understanding of the 
prevalence of VHD in our population, and improved methods of predicting 
outcomes, are essential if we are to be better equipped to meet the challenges of this 
new “epidemic”.  This thesis aims to improve our knowledge of the prevalence of 
VHD in the elderly, and the potential benefits of cardiac magnetic resonance (CMR) 
assessment of patients with clinically significant mitral regurgitation.  
The prevalence of undiagnosed valvular heart disease in those aged 65 and over is 
examined in Chapters 2 and 3. Chapter 2 outlines a population-based screening study 
for VHD in primary care in Oxfordshire, which the author played a central role in 
establishing. The results show that VHD is extremely common in this cohort, and is 
strongly associated with increasing age. In chapter 4, the level of anxiety provoked 
by screening for VHD is looked at; this demonstrates that only a small number of 
patients have significant anxiety levels, but it is more likely in those with a new 
diagnosis of VHD, and in women. 
From Chapter 5 onwards, the thesis focuses on the use of CMR in patients with 
significant mitral regurgitation (MR). In Chapter 5, the clinical value of quantitative 
assessment of MR using CMR is examined, showing that it was able to predict 
progression to symptoms or surgery in these patients.  
In conclusion, this thesis offers insights into the prevalence of VHD in the elderly 
population, and looks at the anxiety associated with looking for VHD in this group. 
The potential clinical benefits of CMR in patients with MR are examined, and 
quantification of MR with this modality would appear to be of prognostic utility. 
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Lay summary 
In the modern era, heart valve disease (VHD) in the developed world is mostly 
related to the ageing process. With an ageing population, the burden of VHD is likely 
to increase. Despite this, the frequency of VHD, risk factors for developing it, and 
ways of predicting how it will progress remain poorly understood. Better knowledge 
of these factors is essential in meeting the challenges of this new “epidemic”.  The 
work presented in this thesis aims to improve our understanding of the prevalence of 
VHD, and the potential benefits of using cardiac magnetic resonance (CMR) 
assessment of patients with a disease affecting the mitral valve (MR).  
The first section of the thesis looks at how frequent VHD is in those aged 65 and 
over, and looks at factors associated with a diagnosis of VHD. The results from this 
community-based study in Oxfordshire show a high prevalence of VHD, which is 
strongly associated with increasing age. The level of anxiety provoked by screening 
for VHD is examined: only a small number of patients have significant anxiety 
levels, most commonly in those with a new diagnosis of VHD, and in women. 
Next the value of using CMR to assess patients with MR is examined, showing that it 
is able to predict progression to symptoms or surgery in these patients.  
In conclusion, this thesis offers insights into the frequency of VHD in the elderly 
population, and looks at the anxiety associated with looking for VHD in this group. 
The potential utility of CMR in patients with MR is examined, and suggests that this 
test is able to help predict disease progression. 
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Chapter 1: Introduction 
1.1 Background and rationale for the studies 
In the late nineteenth and early twentieth centuries, the face of valvular heart disease 
(VHD) began to change. Until that time, rheumatic fever and its sequela of rheumatic 
valve disease had been a highly prevalent cause of cardiac morbidity and mortality. 
Improvements in living conditions led to a decline in this prevalence, which 
continued with the subsequent introduction and widespread use of penicillin(1-4).  
Valvular heart disease in modern, developed countries is a very different entity and  
rheumatic VHD is now rare in Europe(5), but remains common in developing 
countries(6, 7) and represents a significant public health burden to countries with 
scarce healthcare resources to tackle it.  
Degenerative VHD is now the commonest cause of valve disease in developed 
countries(5), and is associated with increasing age according to the data available( 8, 
9). The projected rapid rise in the elderly in the population of developed countries 
can therefore be expected to result in a parallel increase in the burden of VHD in 
these countries. Delays in detection or treatment of VHD may result in significant 
morbidity and mortality, and Davies et al showed that it remains an important cause 
of heart failure and hospital admission(10). Appropriately timed interventions 
improve survival, but when treatment is delayed, worse outcomes have been 
demonstrated(11, 12). Conventional surgical interventions are well established, and 
newer percutaneous options are gaining an increasing evidence base(13-15).  
Despite an awareness that VHD is common, and increases with age, precise 
contemporaneous epidemiological data are scarce, and there have been no 
prospective community-based studies of contemporary VHD in the developed world. 
Lacking such epidemiological data restricts the ability of healthcare planners and 
economists to plan accurately for the future resources likely to be needed for these 
conditions. 
  MD Thesis: Joanna d’Arcy 
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To date, the majority of studies of the prevalence of VHD have been retrospective, or 
focussed on aortic valve disease. Although most studies have been population- or 
community-based, the Euro Heart Survey also provided an insight into VHD seen in 
secondary care(5).  
In the Euro Heart Survey on Valvular Heart Disease, Iung et al looked at 
contemporary VHD in European patients with respect to their characteristics, 
management and outcomes; they also assessed adherence to guidelines(5). Looking 
at 92 centres across 25 European countries, they prospectively gathered data on 5001 
patients with native VHD of at least moderate severity, infective endocarditis, or 
with previous valvular intervention. The commonest valve lesion seen in hospital-
based practice was aortic stenosis (AS). Degenerative aetiology accounted for the 
majority of aortic valve disease and regurgitation; mitral stenosis accounted for just 
under 10% of native VHD, and was rheumatic in origin in 85%. In the assessment of 
outcomes and management, the Euro Heart Survey reported that just under one third 
of patients seen in hospital-based care for symptomatic severe VHD of a single 
native valve did not have any intervention. The reason for this was often cited as 
being because the patient's symptoms responded to medical therapy, which is a 
source of concern. Age was also the commonest “comorbidity” cited by respondents, 
although was rarely the sole reason for intervention being avoided. Although the 
Euro Heart Survey data provide excellent insights in to European VHD practice in 
secondary care, and the modern pattern of VHD seen there, it cannot be used to 
predict the population prevalence of VHD, particularly primary native VHD. The 
constraints of a survey such as this preclude in-depth study of individual reasons for 
lack of intervention, but medical management as an alternative suggests a need for 
significant education in this area. 
Another hospital-based study of VHD looked retrospectively at aortic valve 
disease(16). Berry et al used a case records identification technique to look at 
associations with aortic stenosis in particular. They report an iincreased risk of death 
associated with AS compared with AR or mixed aortic valve disease. Amongst 
patients with AS, a lower risk of death was seen with female gender, hypertension 
and the year of admission. Older patients, those of female gender, and those with 
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comorbidities were less likely to undergo aortic valve replacement. The insights into 
the under-representation of female patients for aortic valve replacement warrants 
further investigation, and may be a source of concern. The hospital-based nature of 
this study however makes it difficult to be sure whether this is applicable to the wider 
female population with aortic valve disease, or simply those requiring hospital 
admission for VHD.  
Widely regarded as a landmark study of the contemporary prevalence of VHD in the 
developed world, the study by Nkomo et al looked at the echocardiography of over 
28,000 patients, and looked for the prevalence of VHD of at least moderate severity. 
Data in nearly 12,000 of the echo studies were taken from three large 
epidemiological studies, which had protocols involving well-defined 
echocardiographic criteria including thorough valvular assessment. These individuals 
represent a random population sample. The remainder of the patients were drawn 
from community-based echo studies within a population with good access to echo. 
These scans were performed for clinical indications following contact with 
healthcare professionals. Nkomo demonstrated a striking association between 
prevalence of VHD and increasing age, with a prevalence of 0.7% in those aged 18-
44 years, increasing to 13.2% in those aged ≥75 years in the population-based 
studies. This association was present in men and women, and in the community-
based data. Mitral regurgitation (MR) was the most commonly detected valve lesion 
in both community- and population-based studies, and mitral stenosis (MS) was the 
least common lesion. Nkomo's study provides valuable information on the 
prevalence of VHD, although it relies on retrospective data from a variety of sources. 
It suggests that in the most elderly segment of the  population, there is clinically 
significant VHD in more than 1 in 10 patients. As discussed further below, this will 
present an increasing problem as the ageing population expands. The difference in 
detection rates of VHD between the community-based, clinically indicated studies 
and the population-based and unselected studies highlights that there is pool of 
undiagnosed VHD which is not detected  in clinical practice. To further assess this, 
prospective focussed studies would be beneficial. As the study was retrospective and 
based upon pooled data from other sources, original echo scans were not directly 
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examined by the investigators. However, the population based studies had well-
defined, prospectively determined protocols for echocardiography, which included 
interrogation of the valves and therefore little in the way of VHD is likely to have 
been under-diagnosed. In clinically indicated echocardiography, there is the 
possibility that the severity of VHD might be underestimated if the clinical indication 
does not suggest VHD as an underlying cause. Echocardiography in the population-
based studies was performed between 1989 and 1996, and therefore these data are 
already over twenty years old; data in the community-based study are also between 
fifteen and twenty years old. Intervention and imaging in VHD has changed 
significantly over this period, and updated data are warranted. The ethnic diversity of 
the participants in these studies is reflective of the diversity seen in the United States 
(40% black, 59% white, 1% other in the population-based studies; 2.7% black and 
90.3% white in the community-based study), but this is not the ethnic diversity seen 
in the United Kingdom. The population of England & Wales is approximately 95.5% 
white, 2.6% Asian, and 1.3% Black(17). Although this is closer to the ethnic mix 
seen within the community-based study than the population-based studies, it is still 
difficult to be confident that Nkomo's data can be extrapolated to the United 
Kingdom, and also to a wider European view. 
Several large epidemiological studies have analysed their cohorts retrospectively to 
glean further information on the prevalence and risk factors for VHD. Some have 
focussed on specific populations, which makes it difficult to extrapolate their data 
more widely; other have focussed only on aortic valve disease, without assessment of 
the mitral valve. The Strong Heart Study looked at a range of cardiovascular risk 
factors, and aimed to ascertain the prevalence and incidence of certain cardiac 
conditions among thirteen American Indian tribes in the United States. The 
prevalence of aortic regurgitation, and associated factors, was reported by Lebowitz 
et al(18). Amongst this selected population, AR was associated with increasing age, 
aortic root size, the presence of AS and MS, and the absence of diabetes. Jones et al 
reported on the findings related to mitral regurgitation in the same population(19), 
and again MR was related to increasing age and presence of MS; in addition lower 
body mass index, female gender, previous myocardial infarction, and presence of 
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mitral valve prolapse were also found to correlate with the presence of MR. These 
data provide a valuable picture of VHD within this specific population, but the lack 
of diversity amongst study participants means that these results cannot be 
extrapolated beyond North American Indian populations. The data are also now from 
scans done twenty years ago, and assuming that the prevalence and clinical correlates 
are the same now is challenging. 
Retrospective studies focussing on aortic valve disease have been published from 
Norway and Iceland(9, 20). The Tromsø Study looked at a cohort of patients within 
an original longitudinal epidemiological study from a city in northern Norway(9). 
The selected cohort underwent echocardiography, including assessment of the aortic 
valve, and associations, outcomes and progression were assessed. Age was again 
strongly associated with an increasing prevalence of AS, rising from 0.2% in those 
aged 50-59 years to 9.8% in these aged 80-89. The investigators also demonstrated a 
mean rate of progression of AS of 3.2mmHg per year. Asymptomatic AS and aortic 
valve replacement were not found to be associated with increased mortality 
compared to the general population. As well as only focussing on AS,  a further 
limitation to this study is that data from hospital-based echo studies were included in 
the analysis, alongside the data from study participants. These hospital-based studies 
were done in response to a clinical indication, which is likely to introduce bias in to 
the results. 
The AGES-Reykjavik study data presented by Danielsen et al also looked at AS, 
without considering other valve lesions(20). The original AGES-Reykjavik study 
was not aimed specifically at VHD, but echocardiographic and cardiac computed 
tomography (CT) data were obtained in a subset of participants. The use of 
echocardiographic data demonstrated that among those aged ≥80 yrs, the prevalence 
of severe AS was 7.3%, and the authors highlighted the potential for VHD to become 
a significant problem associated with an ageing population. The lack of specificity 
for valve assessment in the study cohort means that the prevalence of AS may have 
been prone to a minor underestimate. The long follow up time of participants in this 
study cohort may provide useful extra information on progression and outcomes. The 
investigators also calculated a calcium score on cardiac CT which they found to be 
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equivalent to severe AS on echocardiography. With the increasing use of cardiac CT 
in routine clinical practice, this may assist in the detection of significant VHD in the 
wider patient population. 
There have been a variety of studies looking at various aspects of VHD. Some have 
looked at hospital-based care of VHD, others have looked at specific ethnic 
populations or individual valve lesions; most are retrospective. OxVALVE PCS is 
the only contemporary, prospective screening study aimed specifically at the 
detection of VHD in the developed world. 
Current practice for the management of VHD is based on guidelines which rely 
heavily on consensus of opinion(21-23), and include data from studies which may 
now be outdated. Newer data would perhaps suggest that more proactive approaches 
to the intervention may be appropriate, especially in the most severe forms of 
VHD(24, 25), but further evaluation of this is required, and is being actively 
encouraged by national societies(26).  
In order to optimise the delivery of care to patients with valvular heart disease, a 
clearer understanding of the population affected is required, alongside expert follow-
up and imaging services, armed with a toolkit for accurate risk stratification. At 
present there are many areas of valvular heart disease where the management is 
unclear or a source of debate. How big is the problem of valve disease at present, and 
how many might it affect in future? Which patients need to be followed up, and who 
might be safely be left alone? Are there any options for slowing disease progression? 
When should truly asymptomatic patients with severe VHD have surgery? This 
thesis aims to provide some insights into aspects of these unanswered questions, 
including providing an insight into the contemporary epidemiology of VHD in the 
elderly population, thus helping to define the size of the problem. It also looks at the 
contribution of cardiac magnetic resonance imaging in the quantification of primary 
mitral regurgitation, and how this might assist with risk-stratification in this group. 
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1.2 Defining the size of the problem 
According to the data available, the prevalence of VHD increases dramatically above 
the age of 65, with an estimated prevalence of  0.9% in those aged 18-64 and 9.9% in 
those ≥65 years of age(8). These data are based on pooled data from population-
based studies, undertaken over a quarter of a century ago, and which were not 
undertaken specifically to look for valvular heart disease. The proportion of the 
population aged over 65 is increasing across the developed world. Over the last 
decade, the proportion of the population in this age group has increased by an 
average of 1.9% in the countries of the European Union (EU)(27). This increase in 
the elderly section of the population is predicted to continue, and will bring with it 
many challenges for healthcare resource planning. Figures 1.1 and 1.2 show the 
change in the EU population between 2001-2013, and the predicted change in the 
population age structure in the future. The increase in longevity of our population is 
anticipated to be accompanied by an increase in age related conditions, among them 
valvular heart disease as highlighted by a recent editorial(28). Appropriate planning 
and adequate resource allocation to deal with this increase will only be possible with 
an up-to-date epidemiological picture. Epidemiological studies of VHD may also 
allow the identification of groups of patients with well-defined VHD of all severities. 
These groups may be suitable for studies of progression, medical therapies, novel 
biomarkers, or different surgical interventions. 
Figure 1.1 EU population pyramid showing the change in each age group from 
2001 to 2013. (From Eurostat) 
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1.3 Echocardiography for the detection of VHD 
The data from the United States (US), published by Nkomo et al(8), highlight the 
difference in the detection rate of VHD when echocardiography is performed with 
clinical indications, and that estimated from population-based studies (1.8% vs 
2.5%). Clinical auscultation for valve disease has the benefit of being low-cost, 
easily accessible and non-invasive. It can be used opportunistically for the detection 
of cardiac murmurs, and VHD may be an incidental finding during examination for 
an unrelated issue. However, auscultation is well-recognised as having a limited 
sensitivity for the detection of VHD(29, 30) and should not be relied upon to uncover 
all valve disease. The level of proficiency in auscultation amongst primary care 
doctors is reportedly as low as 40%(31, 32). This is a source of concern in a 
condition in which symptoms occur late and are a harbinger of adverse outcomes, 
and which currently requires opportunistic detection to prompt further investigation 
and ongoing surveillance. Transthoracic echocardiography (TTE) is known to 
maximise the detection of valvular heart disease(6, 8), and has well-established 
national and international guidelines(33-35). It is safe, portable, non-invasive, 
reproducible, cost-effective, and widely available. It does not rely on doctors to 
perform it, but can be expertly carried out by appropriately trained and experienced 
physiologists.  A single comprehensive study can permit assessment of valve 
Figure 1.2 EU population age structure 2013-2080 (From Eurostat) 
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morphology, severity of valve disease, and the effect on the ventricle. These features 
all make it an ideal tool for screening studies for VHD, investigating a newly-
detected murmur, and for longitudinal follow up of those with established VHD.   
Current detection of VHD relies heavily on clinical auscultation, which has its 
deficiencies as already described, and also on incidental detection of VHD when 
echocardiography is performed for reasons other than murmurs. Despite published 
criteria for the use of echocardiography, echocardiography may not be fully utilised 
in the detection of VHD(36). Deficiencies in the reliance on auscultation and 
appropriate echo use are likely to contribute to the significant number so patients in 
the United Kingdom who undergo valve surgery with NYHA class III or IV 
symptoms(37). The awareness of VHD amongst patients is also low, according to a 
recent survey reported by a British Heart Valve charity(38). This lack of awareness 
may contribute to the late presentation to health services with symptom onset. 
The utility of routine echocardiographic screening for VHD would require significant 
investment in resources and personnel. The potential cost benefits of such an 
intervention would require in-depth analysis of the costs of screening and the 
anticipated savings and benefits which it might produce; such an assessment was not 
the intention of the work presented in this thesis, and this is therefore not assessed. 
Indiscriminate population screening may also risk turning healthy people into 
patients, as well as providing inappropriate false reassurance(39, 40). Any potential 
screening programme should target those at the highest risk, including older patients, 
those with hypertension, coronary disease, dyslipidaemia or renal dysfunction(9, 41, 
42). The British Heart Valve Society have even suggested that hand-held 
echocardiography may be useful when access to full echo services is 
challenging(43). They suggest that hand-held echo could be used as a filter to 
determine which patients require full echocardiography. This approach may avoid 
over-stretching busy echo departments with well people. 
In due course, it may be possible to risk stratify people individually through a 
combination of clinical risk factors, serum biomarkers and even genetic screening. 
Until such time as this becomes a reality, all clinicians need to have a high index of 
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suspicion of VHD in patients with risk factors, examine them thoroughly when the 
opportunity presents, and refer for echo when appropriate. 
The first part of this thesis describes the development, methods and results of the 
OxVALVE Population Cohort Study (OxVALVE PCS). This prospective, 
community-based, echocardiographic screening study in the Oxfordshire population 
aged 65 years and older aims to shed light on the present-day epidemiology of VHD 
in a developed country. Detailed demographics and medical histories are captured, 
allowing the possibility of risk factor profiles for VHD to be established. By setting a 
low threshold for a positive screen, patients with milder forms of VHD are captured, 
who may be suitable for future studies aiming to elucidate the pathophysiology and 
natural history of different forms of VHD. Those identified as having more advanced 
VHD may be suitable for inclusion in other ethically approved studies, which may 
perhaps be interventional - medical, surgical or percutaneous - or imaging-based. 
Participants in OxVALVE PCS also provide blood samples, which can be used for 
DNA analysis, as well as for the measurement of biomarkers. Genetic analysis may 
allow markers of increased risk, or of more rapid progression, to be identified and 
studied, while testing for biomarkers may be for those molecules already identified 
as potentially useful in VHD(44-47), or those identified in the future.  
Thus OxVALVE PCS may lead to an improved understanding of the epidemiology 
of VHD in the most at-risk section of the population, allowing better healthcare 
planning, and the evolution of structured screening, surveillance and referral 
protocols in those identified as having VHD. Increased awareness of the risk and 
appropriate management of VHD among primary care clinicians may be another 
consequence of involvement in screening. 
1.4 Pathogenesis, pathophysiology and natural 
history of valvular heart disease 
The mechanisms involved in the development and effects of valvular heart disease as 
a whole remain poorly understood compared with other areas of cardiovascular 
medicine. Although the mechanisms underlying the development and progression of 
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aortic stenosis have become better elucidated in recent years, those underlying aortic 
and mitral regurgitation are less well defined; the relative rarity of mitral stenosis in 
the developed world also means that many aspects of this are particularly challenging 
to study. The natural history and factors affecting progression differs between   
individuals, as well as between lesions. Improvements in understanding in these 
areas may lead to the development of efficacious medical intervention, improved risk 
stratification and more streamlined approaches to surveillance with timely surgical 
intervention as a result. As the most common clinically significant forms of VHD are 
those affecting the aortic and mitral valves(5, 8), the discussion on pathogenesis and 
pathophysiology of VHD below is restricted to these valves. 
1.4.1 Aortic stenosis 
1.4.1.1 Pathogenesis and pathophysiology of aortic stenosis 
Aortic stenosis (AS) is the commonest valve lesion seen in clinical practice(5, 41), 
and affects around 2% of the population in those aged over 65(42). Aortic stenosis is 
characterised by thickening and stiffening of the valve leaflets, resulting in 
progressive narrowing of the valve, with a resulting increase in after load on the left 
ventricle. Calcific aortic stenosis is the commonest cause in developed countries, 
although rheumatic and congenital AS are also seen in a small proportion of cases.  
Bicuspid aortic valves (BAV) are also affected by AS, in a similar way to tricuspid 
aortic valves. The markedly abnormal mechanical stresses to which the valve is 
exposed result in more accelerated stenosis. Rarer causes of AS are seen in 
association with conditions such as hyperparathyroidism, Paget’s disease and 
systemic lupus erythematosus. 
Calcific aortic stenosis is no longer viewed as simply a process of “wear and tear” on 
the valve, although the term “degenerative” AS is still frequently used. Similar 
mechanisms to those involved in the development of atherosclerosis have been 
implicated in the development of calcific AS. Epidemiological studies have 
demonstrated common risk factors for AS and atherosclerosis(42, 48, 49), and 
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histological studies have also supported this. However, up to half of those with 
calcific AS do not have clinically significant atherosclerosis(50). Damage to the 
endothelium of the aortic valve as a result of mechanical stress leads to infiltration of 
the valve with inflammatory cells and lipids. Lesions seen in the early stages of 
aortic valve disease have been shown to contain the same lipids as seen in 
atherosclerosis (such as low-density lipoprotein and lipoprotein (a))(51, 52). The 
presence of these within the valve stimulate an inflammatory reaction, with the 
release of cytokines and infiltration with inflammatory cells(53-55). The role of 
inflammation in the development and progression of aortic stenosis is also supported 
by the finding of increased levels of C-reactive protein in patients with AS(56), and 
the finding of increased 18F-sodium fluoride (18F-NaF) and 18F-
fluorodeoxyglucose (18F-FDG) levels on positron emission tomography. Dweck et 
al showed that levels of both 18F-NaF and 18F-FDG were increased in patients with 
AS when compared with levels in controls(57). They also demonstrated an increase 
in uptake of both tracers correlating with increasing severity of AS, although this 
correlation was stronger for 18F-NaF than 18F-FDG. 
Subsequent fibrosis and calcification resulting from the inflammatory process give  
rise to progressive thickening of the valve. Myofibroblasts and other inflammatory 
cells in the valve leaflets secrete matrix metalloproteinases, leading on to 
remodelling of the leaflet matrix(55, 58). The process of fibrosis in the aortic valve 
also involves the renin-angiotensin system, and angiotensin-converting enzyme 
(ACE) has been shown to be present in stenotic aortic valves, but not in controls(59). 
The potential for altering outcomes in AS by targeting the renin-angiotensin system 
has therefore become a focus of recent studies(60, 61). 
Calcification of the aortic valve can be seen from the early stages of AS, and 
progression from aortic sclerosis may be due to the acceleration of this process as 
myofibroblasts differentiate into osteoblasts. Valvular calcification is well 
demonstrated by computed tomography, which can be used to quantify the degree of 
calcification(62, 63). The severity of this calcification has been shown to correlate 
with disease progression and outcomes, as well as with severity of AS(64-66). The 
presence of these osteoblasts leads on to more advanced calcification, and Mohler et 
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al have demonstrated the presence of bone formation and remodelling in end-stage 
AS(67). 
Although AS and atherosclerosis share a variety of risk factors, they do not always 
co-exist. The failure of drug interventions used in atherosclerosis to have beneficial 
effects in AS suggests that the pathophysiological processes involved diverge. The 
increasing severity of valvular stenosis, which is related to the degree of calcification 
of the valve, is what drives outcomes in AS, rather than underlying inflammation 
itself. 
Aortic stenosis is not just a disease affecting the aortic valve, but the effects of AS on 
the left ventricle (LV) are of pivotal importance also. Although declining left 
ventricular function is an indication for consideration of surgery in those with severe 
aortic stenosis according to current guidelines(21, 68), a reduction in left ventricular 
ejection fraction is only seen late in the disease and is associated with a poor 
prognosis(69). Recent studies have suggested that the response of the myocardium to 
AS, including changes in the geometry of the LV, LV strain, and fibrosis, may be 
important in the prognosis of patients with asymptomatic aortic stenosis(70-72).  
As AS progresses, the valve becomes increasingly stiff with a decreasing valve area. 
This results in an increasing pressure gradient across the aortic valve, reflecting the 
greater pressure required from the LV in order to maintain blood flow across the 
valve; this leads to progressive hypertrophy of the LV. The development of left 
ventricular hypertrophy (LVH) helps to normalise afterload, and it might be expected 
that the degree of LVH would correlate with severity of AS. However the degree of 
left ventricular hypertrophy does not correlate well with stenosis severity(73-75).  
Certain groups of patients, most notably elderly women, appear to have greater 
degrees of LVH than is needed in order to normalise wall stress(76). Concentric 
LVH has also been shown to lead to abnormal coronary blood flow(77, 78). More 
recently evidence has suggested that more extreme degrees of LVH may be 
maladaptive and associated with poorer outcomes. In the Simvastatin and Ezetimibe 
in Aortic Stenosis study, Rossebo et al showed LVH on echocardiography to be 
associated with poor prognosis(79). LVH in asymptomatic patients with AS is an 
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independent risk factor for cardiovascular events(80), and in those undergoing aortic 
valve replacement it is associated with an adverse prognosis(81, 82). Conversely, 
Kupari et al found that those patients with AS who had concentric remodelling but 
no LVH were likely to have the best outcomes(74). 
Left ventricular remodelling response to pressure overload involves a variety of 
complex factors, including genetic factors, co-morbidities and gender(83-86). Gene 
polymorphisms encoding for ACE have been shown to influence both hypertrophy in 
response to AS, and remodelling following aortic valve replacement(83, 87). Greater 
wall thickness and smaller LV cavity size have been demonstrated in females with 
AS when compared to males(88), but following valve replacement hypertrophy 
regresses faster in women(85). In the presence of metabolic syndrome and diabetes, 
more pronounced LVH has also been shown(84, 86). 
Alongside the process of left ventricular hypertrophy, a reactive diffuse interstitial 
fibrosis occurs in patients with AS(89). The mechanisms which drive this process 
involve numerous complex mechanisms. Several of these are common to the 
processes involved in fibrosis occurring within the aortic valve. Increased pressure in 
the LV, such as is seen in AS, leads to local cell damage(90), and chemokines such 
as transforming growth factor beta (TGFβ), matrix metalloproteinases (MMPs) and 
angiotensin II are released. This attracts inflammatory cells into the extracellular 
matrix, which then bind to integrin(91). Pathways involving TGFβ and angiotensin II 
lead to increases in collagen I and III(92). 
Diffuse myocardial fibrosis can be quantified by biopsy, but this is an invasive 
procedure and may be subject to sampling error. Non-invasive assessment of 
myocardial fibrosis can be undertaken using late gadolinium enhancement techniques 
on cardiac magnetic resonance imaging, tending to show a pattern of midwall 
fibrosis in patients with AS. Midwall fibrosis has been shown to be an independent 
predictor of mortality(71, 93). This adverse prognosis is likely to be due to adverse 
remodelling of the ventricle, poorer LV function, as well as arrhythmia. 
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The pathogenesis and progression of AS are complex processes. AS shares risk 
factors with atherosclerosis, but once inflammation has been established, 
calcification of the valve supervenes leading to progressive narrowin(94)g and 
increased LV afterload. The response of the LV to the increased afterload may be 
maladaptive, leading to excessive hypertrophy associated with fibrosis. The rate of 
progression of AS and LV adaptation vary, and complex pathways are involved. 
1.4.1.2 Natural history of aortic stenosis 
 
The development and progression of AS occurs over a long timespan(69, 95), 
although the rate of progression is highly variable. In patients with sclerotic aortic 
valves only a minority will progress to haemodynamically significant stenosis in a 
five year period(96, 97). The development of stenosis is present, the severity 
progresses in nearly all patients, resulting in many requiring intervention on the 
valve(98, 99). Otto et al followed 123 patients prospectively and found an average 
increase in the mean transvalvular gradient of 3-10mmHg per year, 0.1-0.3m/s 
increase in the peak velocity across the valve, and an average fall in valve area of 
0.1cm2 per year(98); rate of progression was associated with transvalvular jet 
velocity at baseline, rate of change of jet velocity and patients’ functional status. 
Other factors associated with more rapid progression of AS include age, gender, 
renal dysfunction and hyperlipidaemia(100), calcification of the valve as measured 
by cardiac CT(101, 102), and also sodium fluoride uptake on PET-CT(103, 104). 
The rate of symptom onset is also highly variable. Risk factors for symptom onset 
are similar to those associated with more rapid progression of AS, including gender, 
age, severity of stenosis and functional status. Jet velocity is strongly predictive of 
rate of symptom onset: those with a jet velocity below 3.0m/s have the lowest rates 
of symptom onset, and those with a jet velocity over 4.0m/s having the highest 
rates(98). Those with severe disease may remain symptom-free for some time, but 
those most at risk progressing to symptoms include those with more calcified valves, 
and those aged over 50 years(65, 105). When AS becomes very severe (maximum 
velocity greater than 5.0m/s), the rate of symptom onset is sufficiently high that 
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consideration may be given to valve replacement before symptoms are reported(25, 
106). 
The commonest symptom seen in severe aortic stenosis is decreased exercise 
capacity due to breathlessness(98). This may be difficult to detect if patients 
subconsciously limit their activities in order to avoid provoking their symptoms. The 
onset of angina is a common symptom of severe AS, even in the absence of coronary 
disease, and Horstkotte et al found a mean survival of 45±13 months after the onset 
of angina; mean survival with syncope and heart failure was 27±15 months and 
11±10months respectively(107). 
1.4.2 Aortic regurgitation 
Aortic regurgitation (AR) is less common than aortic stenosis, and accounts for 
approximately 10% of VHD seen in the hospital setting(5), and the majority of AR is 
chronic. Chronic AR may result from primary abnormalities of the valve with leaflet 
prolapse or malformation, myxomatous degeneration of the valve, and as a result of a 
bicuspid aortic valve. It may also be secondary to dilatation of the ascending aorta, 
with annular dilatation and failure of leaflet coaptation. Aortic dilatation may be due 
to hypertension, or Marfan’s syndrome and other connective tissue disorders, such as 
Ehlers-Danlos syndrome or osteogenesis imperfecta. Thickening and retraction of the 
leaflets of the aortic valve may be seen following rheumatic fever, resulting in 
central aortic regurgitation, but this is a rare cause of AR in developed countries. 
Aortitis due to ankylosing spondylitis, rheumatoid arthritis, giant cell arteritis, or 
syphilis (now rare) may result in AR. However, in up to a third of cases of pure AR, 
the aetiology has been described as unclear in a pathological study examining valves 
excised at surgery(108).  
Acute AR is much less common than chronic AR, and is associated with traumatic 
injuries to the aortic valve and aorta, or aortic dissection involving the aortic root and 
valve. It may also complicate infectious endocarditis, with leaflet tearing or when 
perivalvular abscess results in a communication between the aortic root and LV. 
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As with aortic stenosis, the effect on the left ventricle is of great importance in how 
the lesion is tolerated. Studies suggest that over time the regurgitant orifice area 
increases in size, resulting in increased volume and pressure loads on the LV(109). In 
chronic AR, compensatory mechanisms of the LV initially maintain cardiac 
performance. These mechanisms include increases in end-diastolic volume, an 
increase in LV compliance, and both eccentric and concentric hypertrophy. An 
increase in total stroke volume is required, in order to eject forward stroke volume in 
addition to regurgitant volume. The degree to which total stroke volume is increased 
is dependent on the severity of the AR, and it has been shown that the greatest 
increases in LV mass and volumes occur in those with more severe AR(110). 
Increasing LV dilatation provides a greater diastolic volume, thus permitting a larger 
total stroke volume. This is achieved by rearrangement of myocardial fibres, and the 
addition of new sarcomeres and subsequent eccentric hypertrophy(111). Increasing 
chamber size is associated with increasing systolic wall stress, resulting in further 
hypertrophy(112), and so increasing LV volumes are associated with increasing LV 
mass. With increasing disease progression, normal ejection fraction is maintained, in 
spite of increased afterload, by compensatory hypertrophy and recruitment of preload 
reserve(113-115). This balance cannot be maintained indefinitely, and a decline in 
LV function occurs. The point at which this occurs is difficult to define, and cannot 
be precisely identified by a single measurement at present.  
In the setting of acute AR, these compensatory mechanisms do not have the time to 
take place. The effect on the left ventricle is therefore much more abrupt. Left 
ventricular end diastolic pressure increases rapidly, and pulmonary oedema ensues. 
Severe acute AR results in a rapid fall in cardiac output, and cardiogenic shock may 
develop. In order to try and compensate for the drop in cardiac output, a tachycardia 
develops. Lower myocardial perfusion pressure due to severe acute AR, in 
combination with increased cardiac work, leads to myocardial ischaemia, and a 
further decline in cardiac function(116). A downward cycle of dysfunction sets in, 
unless rapid intervention to correct the regurgitation can be undertaken. 
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1.4.3 Mitral regurgitation 
Mitral regurgitation (MR) is the most commonly detected form of valve disease in 
developed countries(8), and is the second commonest lesion requiring 
intervention(5). It can be either primary MR, due to processes such as myxomatous 
degeneration, or secondary to pathology affecting the muscle of the left ventricle, 
such as ischaemia or underlying cardiomyopathy. Infective endocarditis is also an 
important cause of MR(5, 117). The natural history of secondary MR relates to the 
underlying cause, and best approaches to its management remain a source of debate.  
Although degenerative MR can result from mitral annular calcification in a few 
cases, the commonest cause of chronic, isolated MR is mitral valve prolapse 
(MVP)(118, 119). MVP is defined as prolapse of 2mm or more, of either or both 
leaflets of the mitral valve, above the valve annulus as seen in the parasternal long 
axis and other views(21). Using this definition, the prevalence of MVP is between 2-
3%, with an equal gender distribution(120). Milder degrees of MVP may occur 
without significant regurgitation if coaptation of the leaflets is maintained. Moderate 
MVP is considered to be that when the leaflet tips remain in the left ventricle, and the 
body of the leaflets “billow" into the left atrium (LA). In severe MVP, the leaflet tip 
everts completely into the LA; this is often associated with rupture of one or more of 
the chordae tendinae. MVP is multifactorial, resulting from various connective tissue 
disorders such as Marfan syndrome, Ehlers-Dalos and pseudoxanthoma elasticum; 
differences in the geometry of valve and ventricle, such as excess leaflet tissue, 
excessive chordal extension, or small LV cavity size; or in association with 
histological changes within the valve tissue, known as myxomatous degeneration, 
which result in leaflet thickening and redundancy. 
The normal tissue of the mitral valve leaflets consists of three layers: the atrialis 
layer is a layer of collagen and elastic tissue, which forms the atrial surface of the 
valve leaflet; the middle layer is termed the spongiosa layer, which is composed of 
structural proteins and proteoglycans; and the ventricularis or fibrosa layer on the 
ventricular aspect of the valve, which is predominantly formed of collagen. 
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Myxomatous degeneration involves changes predominantly to the spongiosa and 
fibrosa. The spongiosa layer has been shown to contain increased numbers of 
interstitial cells. These cells have the properties of activated myofibroblasts, and also 
have increased concentrations of proteolytic enzymes such as matrix 
metalloproteinases, which result in the degradation of elastin and collagen(121, 122).  
Increased proteoglycans and glycosaminoglycans have also been shown to extend 
into the fibrosa and chordae(123). These higher concentrations of proteoglycans 
within the fibrosa are thought to affect the tensile strength of the valve tissue. This 
may be due to dysfunction of the interaction between collagen fibres and 
proteoglycans(124). Changes have also been described to the structure of collagen in 
all three layers of the valve leaflet, with a more diffuse and disorganised pastern of 
distribution of elastin, collagen I and collagen III, compared with normal valve 
structure(122, 125).  
Although some of the mechanisms involved in myxomatous degeneration and MVP 
have been elucidated, triggers for the onset of these remain unclear. As with the 
changes in AS, it has been suggested that exposure of an abnormal valve to repeated 
mechanical stress may be involved in the onset of the pathological process(126). 
Genetics also seem to play a part, although the majority of cases of MVP appear to 
be sporadic. This genetic association was described over forty years ago(127, 128), 
with an autosomal dominant pattern of inheritance. However, the penetrance is 
variable, and the clinical presentation shows marked variation. Although two genes 
associated with this pattern of inherited myxomatous mitral valve prolapse, MMVP1 
and MMVP2, have been identified and mapped to specific loci(129, 130), the 
proteins coded for by these genes remain unidentified. Although polymorphisms 
associated with MVP have been identified, these do not necessarily correlate with the 
degree of severity of MVP. Nasuti et al demonstrated abnormalities in the 
distribution and structure of proteins such as fibrillin, elastin and collagens I and III 
in patients with MVP(131). This gives rise to the possibility that the defect may not 
lie with the proteins themselves, but may be post-translational. Environmental 
factors, as well as age, may affect the penetrance of genetic defects involved in the 
development of MVP, a suggestion supported by data showing that MVP is not seen 
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on echocardiography of newborns(132). MVP is associated with several inherited 
connective tissue disorders. Specific genetic defects in these disorders may give rise 
to a higher prevalence of MVP within these populations. In type IV Ehlers-Danlos  
for example, the production of collagen III is abnormal, and these patients may have 
a higher prevalence of MVP than in other types of Ehlers-Danlos(133). A 
polymorphism in the gene coding for collagen III which has been linked to MVP in a 
group of Taiwanese patients is also located in the region of the known gene 
mutations involved in type IV Ehlers-Danlos syndrome(134). 
Mitral regurgitation associated with infective endocarditis may be the result of 
perforation of the valve leaflets, or to chordal rupture, due to the destruction 
associated with the infection. Endocarditis may occur on a valve already known to be 
abnormal, and MVP with MR is thought to be associated with it due to the presence 
of thickened valvular tissue and turbulent flow across the valve. Data suggest an 
increased risk of between three- and eightfold for patients with MVP and MR, 
resulting in an annual incidence estimated to be approximately 0.02%(135-137), 
although these data are from three decades ago. Various risk factors have been 
suggested for the development of endocarditis in those with known MVP, including 
gender, age, leaflet thickening and redundancy, and the presence of a systolic 
murmur(136-140). 
Mitral regurgitation results in  an increased volume load on the left ventricle, leading 
to the initiation of compensatory mechanisms of the heart and circulation. In acute 
MR, such as may occur with a flail leaflet or chordal rupture, there is a sudden 
increase in volume load in the left atrium and ventricle. This sudden loading on the 
LA results in back pressure on the pulmonary vasculature, with subsequent 
pulmonary congestion. Cardiac output also falls due to the decrease in forward stroke 
volume. Volume overloading of the LV is countered by the Starling mechanism, and 
fractional shortening increases, with decreased LV end-systolic volume due to 
regurgitation into the LA. In response to the decreased cardiac output, a 
compensatory tachycardia occurs. If these mechanisms are not able to compensate 
adequately for the severe acute regurgitation, or if interventions are not promptly 
instituted, cardiogenic shock and pulmonary oedema result. 
  MD Thesis: Joanna d’Arcy 
  36 
In order to adapt to chronic mitral regurgitation, left atrial dilatation occurs with 
increased compliance, and a decrease in LA pressure can be seen. Left ventricular 
dilatation also occurs, due to the addition and rearrangement of sarcomeres(141, 
142), allowing normalisation of the preload on individual sarcomeres. A greater LV 
volume can also be sustained in the presence of normal LV diastolic pressures, and 
systolic wall stress can be restored to normal levels(143-146). LV ejection fraction 
may be normal or high in chronic, compensated MR as a result of these adaptive 
processes, despite the altered left ventricular function(147). In fact, when LV 
ejection fraction is borderline, it is likely to reflect underlying systolic dysfunction in 
this context(148, 149). In the presence of chronic MR, increasing severity of 
regurgitation, along with increasing chamber dilatation, eventually progresses to a 
decompensated stage. Increasing LV dimensions themselves can further impair 
leaflet coaptation, resulting in greater degrees of regurgitation and volume overload. 
The ventricle becomes more globular in shape, resulting in greater systolic wall 
stress(145, 150, 151). 
1.4.4 Mitral stenosis 
Mitral stenosis (MS) is the least frequent left-sided valve lesion, and is most 
frequently a  consequence of previous rheumatic fever(5). The incidence and 
prevalence of rheumatic fever has wide geographical variation, and consequently the 
morbidity and mortality of MS differs between developed and less developed 
countries(6, 152). Many of the studies of MS are very dated, reflecting the decrease 
in prevalence in the developed world over recent decades. 
Rheumatic fever follows infection with Group B haemolytic streptococci in 2-3% of 
patients. Pancarditis results from autoimmune activation involving the M protein 
antigen common to both the heart and the bacterium. A chronic inflammatory 
process results in the valve, with subsequent fibrosis. Progressive commissural 
fusion results in a fixed mitral orifice. Thickened and restricted valve leaflets, and 
fibrosis and calcification of the subvalvar apparatus also contribute to progressive 
stenosis.  
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The natural history of rheumatic MS is difficult to elucidate, as the diagnosis of 
rheumatic fever may be missed, especially in the less mature healthcare systems in 
countries in which it is most prevalent. This is well illustrated by the work of 
Marijon et al, who demonstrated a ten-fold increase in detection rates of rheumatic 
valve disease using a systematic echocardiographic programme compared to 
estimates relying purely on clinical data(153). Studies looking at the progression of 
MS are are all small and retrospective, with a heterogeneous mix of those who 
progressed slowly and those whose valve area decreased more rapidly. Rheumatic 
fever is also often recurrent. Chronic rheumatic valve disease occurs in the majority 
of patients following their first episode of carditis. Meira et al identified potential 
predictors for developing progressive rheumatic valve disease; these included the 
severity of the carditis, low educational level of the patient’s mother, and recurrent 
rheumatic fever(154).  
Other causes of haemodynamically significant MS are rare. Elderly patients may 
have degenerative calcification of the mitral valve annulus, but this only rarely leads 
to significant MS. In such cases where MS does result, it is calcification and 
restriction of the leaflets which is the main process, rather than commissural fusion. 
Conditions associated with chronic inflammation (such as systemic lupus 
erythematosus), carcinoid syndrome, and certain drugs (for example methysergide 
and fenfluramine-phentolamine) may also cause mitral stenosis. All of these 
aetiologies result in predominantly leaflet involvement, with thickening and 
restriction, rather than fusion of the commissures. Congenital causes of MS are 
extremely rare, and tend to involve abnormalities of the subvalvar apparatus. 
The progression of MS leads to an increasing diastolic pressure gradient across the 
mitral valve. This is dependent on mitral valve area, but is also related to heart rate 
and flow across the valve. Trans-valvular flow increases during atrial contraction, 
and this results in an increase in the trans-mitral gradient during this phase of the 
cardiac cycle. However, the onset of atrial fibrillation in the setting of severe MS 
may result in a paradoxical decrease in trans-valvular gradient as the contribution of 
atrial contraction is lost. Atrial fibrillation is common in more advanced MS as the 
high pressure gradient across the valve results in an increase in left atrial pressure.  
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This elevated left atrial pressure leads to dilatation of the left atrium, which in turn 
predisposes to the development of atrial fibrillation; the onset of AF has been 
associated with increased mortality in this context(155). The impaired trans-atrial 
flow due to MS, coupled with the stasis seen with AF, is associated with left atrial 
thrombus formation. The commonest site for thrombi to form is in the left atrial 
appendage(156). 
The left ventricle in MS does not dilate or hypertrophy, but diastolic filling is 
impaired. As a result, the contribution of LV filling due to atrial contraction is more 
significant than normal. This reliance on active LV filling is why the onset of AF 
may result in a sudden worsening of symptoms. 
Following on from the increasing LA pressure, pulmonary artery pressure increases. 
Early changes in the arteries and arterioles involve medial thickening, followed by 
thickening of the intima(157). These changes are thought to be reversible if 
pulmonary pressures decrease, but if not, progression to irreversible changes can be 
seen. These changes include fibrin deposition and infiltration of inflammatory cells 
in the vessel walls, and ultimately the development of plexiform lesions with end-
stage pulmonary hypertension. In response to increasing pulmonary hypertension, the 
right ventricle hypertrophies and dilates, and will eventually fail. However, the 
degree of right ventricular failure in patients with MS does not correlate well(158). 
Asymptomatic patients are report as having an 80% survival at 20 years, although 
one study found a rate of progression to symptoms of 50% by 10 years(159). The 
onset of symptoms associated with MS denotes a poor prognosis. In those patients 
who decline intervention, Horstkotte et al found survival rates of only 44% at five 
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1.5 Mild valvular heart disease. 
The detection of mild valvular heart disease, in particular mild regurgitation, is 
associated with a benign prognosis. European guidelines suggest longer intervals 
between follow up of these patients, and mild mitral regurgitation is not mentioned 
as requiring serial testing(162). However, the study of mild forms of valve disease 
have a number of benefits.  
Early changes in the valve itself may reflect how the valve lesion evolves over time, 
and whether it progresses to clinical significance.  The changes seen in aortic 
sclerosis for example with the deposition of lipoproteins, inflammatory cell infiltrates 
and microscopic calcification, may or may not progress over time to the more florid 
changes seen in aortic stenosis. The reasons why some individuals develop 
progressive AS, while others do not, are unclear. The identification of risk factors for 
progression may provide potential targets for intervention, and highlight those 
individuals who would benefit most from ongoing surveillance. 
The natural history of all forms of valve disease is poorly understood, increasing the 
challenge of follow up and timing of intervention. The assumption that milder forms 
of VHD have benign outcomes may provide a false degree of reassurance for 
clinicians and patients. Even in mild and moderate disease there is evidence to 
suggest that survival is adversely affected(99). Progression of aortic sclerosis to 
stenosis was shown in 16% of patients within 7 years(163). Milder forms of VHD 
cannot therefore be assumed to be inconsequential. Providing information to patients 
about whether they might expect their VHD to require intervention in due course, 
and within what timescale, is challenging with the current gaps in knowledge in this 
area. The longitudinal study of cohorts of those with mild valve disease may provide 
further insights into this aspect of VHD. An improved understanding of the natural 
history of VHD may also allow improved surveillance schedules, assisting with the 
rationalisation of healthcare resources.  
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Medical therapies which reliably retard the progress of VHD remain elusive. 
Although the use of statins in AS providing a period of optimism that they would 
prove efficacious, this has thus far not proven to be the case. Therapeutic 
intervention in the earliest forms of VHD may be required if treatment is to affect the 
pathologic mechanisms before irreversible and progressive changes occur. As 
patients with mild VHD may not be seen in routine clinical practice, their inclusion 
in screening studies may provide a resource for future research. 
The inclusion of participants with mild VHD, including aortic sclerosis, within the 
OxVALVE PCS study will allow the identification of cohorts with the different 
valve lesions for future study. These studies may be interventional, imaging based, 
genetic or looking at other biomarkers of disease. 
1.6 Impact and attitudes to screening 
Although screening programmes may play a vital role in the detection and 
management of certain conditions, there have been concerns raised about the  
potential for anxiety to be provoked by such programmes(164, 165). Various studies 
have been undertaken in order to determine whether there is good evidence for this, 
but have concluded that this is not the case(166). Cardiovascular disease is one of the 
major areas where screening interventions have been employed, and specific studies 
have been undertaken to assess the psychological impact of these, which have 
reassuringly demonstrated no significant adverse psychological or emotional 
impacts(167-169). Valve disease has a less prominent position in the public 
consciousness than many other conditions with well-established screening 
programmes, and the use of echocardiography is unfamiliar to many. An assessment 
of whether or not anxiety might be provoked by actively looking for VHD is 
therefore an important step to avoid potentially adverse psychological and emotional 
outcomes.  
Screening tests need to be acceptable to the target population in order to achieve 
sufficient coverage. If the uptake of screening is too low, it ceases to be cost 
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effective, as well as ineffective. Any screening programme for VHD therefore also 
needs to be acceptable to those at whom it is aimed. 
As an important part of OxVALVE PCS, a questionnaire aimed at assessing the 
levels of anxiety triggered by participation was included. Participants also completed 
a questionnaire to capture attitudes to screening for VHD, as well as how acceptable 
the use of TTE was to this group. The data presented in this thesis also demonstrates 
not only the feasibility of a large-scale screening programme for VHD, but that the 
target population find it an acceptable test, and are not unduly anxious about 
undergoing it. 
1.7 Assessment of mitral regurgitation 
Mitral regurgitation is the second most frequently detected form of valve disease in 
OxVALVE PCS, after aortic sclerosis. Indications for intervention in this group rely 
on the accurate and reproducible assessment of the mitral valve and the left ventricle. 
This is most commonly done by TTE, although this method has significant 
drawbacks, and identification of patients at highest risk for requiring intervention are 
not well defined. This area needs further study, and the second part of this thesis 
includes work in this area. 
1.7.1 Trans-thoracic echocardiography 
Current guidelines for the echocardiographic assessment of mitral regurgitation (MR) 
severity recommend an integrated approach, using quantitative and supportive 
features(33, 170). The use of qualitative assessment alone has a variety of potential 
sources of error, including sensitivity to machine settings, eccentricity of jets, and 
variability according to loading conditions. Quantitation has been linked to 
outcomes(12, 171), but relies on precision and reproducibility. Although there is 
evidence of consistency within single centres(172, 173), this is not necessarily the 
case between centres(174). As with all echocardiographic assessments, adequate 
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image quality is vital. This may be prohibited by inadequate acoustic windows, co-
existent respiratory disease, previous thoracic surgery or unfavourable body habitus.  
Recommendations for the evaluation of regurgitant valve disease include an 
assessment of the overall valve structure and impact of regurgitation on the chambers 
of the heart by TTE. This includes looking for flail leaflets or ruptured chordae, 
valvular calcification or vegetations. The presence of any of these may support an 
assessment of severity of regurgitation, and may also inform clinical decision making 
about the acuteness and impact of a lesion. The anatomy of the mitral valve will also 
influence its suitability for surgical repair. A full assessment of the anatomy may 
require trans-oesophageal echo, but TTE may also provide information on this. The 
assessment of ventricular size and systolic function is not specific to echo for VHD. 
However, appropriate assessment of these helps to inform decision-making for 
timing of intervention. A careful and accurate assessment of these is vital. 
The use of Doppler echo techniques is required to confirm the presence of 
regurgitation, even in an abnormal looking valve on two-dimensional echo. Colour 
flow imaging is used to demonstrate the regurgitant jet in the relevant cardiac 
chamber; in the case of MR, it visualises the regurgitation in the left atrium. This 
should be assessed in at least two anatomical planes, and the echo probe should be 
manipulated to ensure that any jet is optimally visualised. Using colour Doppler, the 
direction of the regurgitant jet into the left atrium can be established. An anteriorly 
directed jet is indicative of posterior leaflet abnormality and vice versa. Colour 
Doppler can be used to assess severity of MR by regurgitant jet area, measurement of 
the vena contracta, or by proximal flow convergence. 
The size of the regurgitant jet in comparison to the size of the LA has been validated 
in studies of patients with regurgitation(175, 176). This method has been 
demonstrated to have a variety of pitfalls, which limit its utility(177). The severity of 
regurgitation may be underestimated in the presence of jet entrainment along the 
atrial wall as the jet will appear smaller(176). The type of echo machine in use, and 
the specific settings on any individual machine (e.g. gain, output power, Nyquist 
limit) will also affect the appearance of the jet. Jet area is also related to blood 
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pressure, which is responsible for driving the pressure gradient across the valve. 
Recording the blood pressure during the echo allows for this to be taken into 
consideration when interpreting the images. Jet area therefore allows for a semi-
quantitive assessment of MR severity, but the limitations of the method should be 
understood.  
Vena contracta (VC) refers to the narrowest diameter of the regurgitant jet, seen at 
the valve orifice or immediately downstream of it. It reflects the size of the 
regurgitant orifice, and has been shown to provide an accurate assessment of MR 
severity(173, 178). VC has been demonstrated to be independent of flow rate and 
pressure across the orifice(179). It is also less affected by machine settings. Dynamic 
changes in the regurgitant orifice area may affect the VC(180), an important 
consideration in mitral valve prolapse with late systolic MR. VC is still accurate for 
the assessment of acute MR, when jet area is less helpful, and in the assessment of 
eccentric MR jets. The small size of the VC means that inaccurate measurement may 
lead to a large error in severity assessment. In order to optimise the assessment and 
measurement of VC, the use of a narrow sector width of minimum depth, with a 
zoomed image(33). 
The use of the Proximal Isovelocity Surface Area (PISA) method for MR assessment 
is in common practice, and has been validated in a variety of studies(181-183). PISA 
relies on the use of colour flow mapping to assess the velocity of blood flow in the 
left ventricle, as it converges on the regurgitant orifice of the mitral valve. Flow 
accelerates towards the orifice, and results in a series of “isovelocity” surfaces, 
which are theoretically hemispheric. More severe regurgitation results in flow 
acceleration at a greater distance from the valve, and larger PISA shells. Appropriate 
image quality, and adjustment of the Nyquist limit to optimise visualisation of the 
PISA, are required, but measurement of PISA can be used to calculate regurgitant 
volume and effective regurgitant orifice area.  
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Like other echocardiographic methods for assessing MR severity, it makes certain 
geographical assumptions. When the regurgitant orifice changes size and/or shape 
significantly throughout systole, such as with mitral valve prolapse and late systolic 
MR, the tendency is for the severity of MR to be overestimated. Non-hemispheric 
PISA may result from the MR jet being constrained by the ventricular wall on mitral 
valve leaflet, again leading to an overestimation in the severity of MR. Multiple jets 
are also challenging for PISA assessment. Each jet requires individual assessment, 
which is time-consuming, and provides the potential for increased error; in addition 
overlapping jets will cause further inaccuracies. Mitral valve prolapse with 
associated MR is an important source of potential error in the use of PISA. Enriquez-
Sarano et al demonstrated that regurgitant orifice area by PISA tended to be 
overestimated in this context, when compared with quantitative Doppler and 2D TTE 
methods(184). Topilsky looked at outcomes according to the timing of MR in the 
cardiac cycle, and the associated quantitative echo measures(185). For identical 
regurgitant orifice area, MR arising in mid-late systole was associated with lower 
calculated regurgitant volume when compared with MR throughout systole. This was 
also associated with more benign outcomes. Topilsky et al suggest that in patients 
Figure 1.3 Proximal isovelocity surface area (PISA) assessment, demonstrating 
flow convergence towards the regurgitant orifice, regurgitant jet, and vena 
contracta; r is the PISA radius. 
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with mid-late systolic MR regurgitant volume may be a more appropriate measure of 
severity than regurgitant orifice area. 
In addition to colour Doppler techniques, the use of pulsed and continuous wave 
Doppler in the assessment of MR is well recognised. Continuous wave (CW) 
Doppler can provide indirect evidence of severity through the signal intensity, 
shapeof the curve, and forward flow velocity across the mitral valve. A poorly 
defined CW Doppler trace without a complete envelope is seen in the mildest forms 
of MR, and severe MR is associated with a dense signal which has a similar density 
to that of the forward flow signal. When looking at the forward velocity across the 
mitral valve, it is important to look for associated MS, which will increase the 
velocity. As severity of MR increases, increasing regurgitant volume leads to greater 
forward flow across the mitral valve. This is associated with an increased forward 
velocity across the valve, which therefore provides supporting evidence of more 
severe MR. 
The assessment of ventricular filling by pulsed wave (PW) Doppler has also been 
evaluated in MR. In a study by Thomas et al, the pattern of ventricular filling 
correlated well with severe MR(186). The finding of a peak E wave velocity of 
>1.2m/s detected severe MR with a sensitivity and specificity of 86% and 86%, and a 
positive predictive value of 75%. This study also demonstrated that severe MR was 
excluded by a filling pattern which had a dominant A wave. 
PW can also be useful for the assessment of regurgitant volume and effective 
regurgitant orifice area (EROA). When PISA is less accurate in cases of eccentric 
regurgitant jets, or non-hemispherical isovelocity surfaces, the use of PW remains 
reliable. The difference between transmitral flow, measured at the level of the mitral 
annulus, and transaortic flow, measured in the LVOT, calculates the  regurgitant 
volume. In order to derive the EROA, the regurgitant volume (by PW) is divided by 
the velocity time integral of the MR jet (by CW). 
Although the quantitation of MR severity by echo is relatively time consuming and 
prone to errors and inaccuracies, its relevance to outcomes has been well 
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documented(12, 187-191). However, practitioners need to be aware of the potential 
pitfalls of methods of quantitation. The reliance on a single indicator of severity 
should be avoided, and guidelines suggest an integrated approach to their use(33). 
1.7.2 Cardiac magnetic resonance 
Over recent years, cardiac magnetic resonance (CMR) imaging has become more 
accessible. It remains relatively costly and time-consuming, when compared to 
2DTTE, but it may provide significant additional information, particularly in 
situations of diagnostic uncertainty. CMR has the ability to provide highly accurate 
and reproducible measures of left ventricular volumes, mass and systolic function, 
and provides unparalleled information about the right ventricle(192-195). Like 
echocardiography, the valve and ventricle can be assessed in the same scan, and the 
reproducibility of measurements facilitates the follow-up of patients with VHD. It is 
not limited by acoustic windows or difficulties with alignment of the Doppler beam, 
although ferro-magnetic implants and significant claustrophobia are contra-
indications to CMR. Cawley et al have also demonstrated a lower inter-and intra-
observer variability for the assessment of valvular regurgitation compared with 
TTE(196). 
One method for CMR quantitation of MR is by calculating the stroke volume 
difference, if there is no other valvular regurgitation. Left and right ventricular stroke 
volumes (LVSV and RVSV respectively) can be calculated from careful contouring 
of short-axis CMR images. RVSV can be subtracted from LVSV to give the 
regurgitant volume(RVol): 
RVol (ml/beat) = LVSV - RVSV 
Regurgitant fraction (RFrac) can then be calculated as a percentage of LVSV, 
according to the formula: 
RFrac (%) = (RVol/LVSV) x 100 
A second method for CMR quantification of MR is the use of phase contrast velocity 
mapping. Phase contrast velocity mapping allows the velocity of blood moving 
through the imaging plane to be measured. This is possible as the moving protons 
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present in the blood flow have a net phase according to the direction of blood flow. 
The net phase is proportional to the velocity of blood, and is displayed by using 
different signal intensities to represent different velocities. When flow is moving in 
the phase-encoding direction set for the image, voxels are bright; flow moving in the 
opposite direction appears dark. Two sets of images are produced by velocity 
mapping. Magnitude images permit the borders of the vessel of interest to be 
visualised. Phase velocity maps display the velocities for each voxel. Images are 
produced throughout the cardiac cycle. Flow can through the imaging plane can 
therefore be quantified by identifying a region of interest using the magnitude image. 
This region of interest is automatically transferred to the phase image. Regions of 
interest can usually also be automatically transferred to all of the frames acquired, 
although manual adjustment to individual frames may be required to maximise 
accuracy. Software for flow quantification integrates the velocities contained within 
each voxel in the region of interest, and all of the velocities from each frame are then 
integrated to calculate the total flow through the cardiac cycle. This can be displayed 
as a flow graph, as well as a display providing peak velocity, forward flow volume 
and reverse flow volume.  
Important limitations of phase contrast velocity mapping include temporal resolution, 
measuring flow in arrhythmias, and errors of phase shift. The temporal resolution of 
velocity mapping is approximately one-tenth of Doppler echo, at 25-45ms.This may 
not be short enough to accurately capture the short time at peak velocity of some 
stenotic jets. Although measurement of flow in phantoms has been shown to 
accurately measure flow in excess of 5m/s(197). As flow data are collected across 
several cardiac cycles, irregular cardiac rhythms can introduce error. In well-
controlled arrhythmias, for example well-controlled atrial fibrillation, these errors    
may not be clinically significant. When arrhythmias have greater beat-to-beat 
variability, such as with frequent ventricular ectopics, large variations in blood flow 
can occur, and flow data must be interpreted with caution. 
As an alternative to the use of stroke volume difference, phase-contrast velocity 
mapping may be used to assess valvular regurgitation, and has been shown to be 
accurate and reproducible for this(198-201). In the case of mitral regurgitation, aortic 
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forward flow is measured, and this is then subtracted from LVSV to calculate RVol, 
and subsequently RFrac. In a study comparing stroke volume difference with flow 
measurement by CMR, Kon et al found the latter to be slightly superior(202). Further 
discussion of the acquisition of phase contrast velocity mapping in the study 
presented here is provided in Chapter 5. 
1.7.3 Prognostication in mitral regurgitation 
CMR quantitation in VHD offers the potential for prognostication, as has been 
shown by recent work from Myerson et al(203). The ability to predict likelihood of 
progression to surgery or symptoms by this method may be a very powerful tool, 
particularly when early intervention with valve repair is feasible. The data presented 
in Chapter 4 of this thesis demonstrate the potential for CMR quantitation of MR to 
offer this potential, using data from four high-volume CMR centres in the United 
Kingdom and New Zealand. Values for RVol and RFrac are presented which 
discriminate well between those likely to develop indications for surgical 
intervention, and those who are less likely to do so. Not only do these data 
demonstrate the potential for identifying those at highest risk of  requiring surgery, 
but may also help to identify those who can potentially be reassured of their low risk 
of progression. 
1.7.4 Comparing methods 
Although the pitfalls of TTE assessment of MR are recognised, there are few data 
comparing them with CMR in this setting. Cawley et al have reported on one such 
study, which look at both aortic and mitral regurgitation (196), with small number so 
each, and suggest that CMR may be superior for serial measurements of 
regurgitation. Van De Heyning et al demonstrated good correlation of planimetry of 
regurgitant orifice by CMR compared with PISA on TTE, but found TTE to 
underestimate severity of left ventricular remodelling in these patients(204).  
In this thesis, data are presented on a sample of 36 patients with mitral regurgitation, 
who underwent 2DTTE and CMR assessment of the severity of the MR. The RVol 
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according to the PISA method on 2DTTE is compared with the RVol measured by 
CMR. The correlation between these two measures in these 36 patients was not as 
good as that seen in other studies. 
1.8 Aims of this research 
This research aimed to investigate the contemporary epidemiology of valvular heart 
disease in a developed country, and to use advanced cardiac imaging to investigate 
the assessment of one form of valve disease, namely mitral regurgitation. The main 
aims were: 
• To investigate the prevalence and correlates of valvular heart disease in the 
population aged 65 years and above, in the Oxfordshire population. 
• To examine the extent and predictors of anxiety provoked by screening for valve 
disease in this population, and to assess the acceptability of trans-thoracic 
echocardiography in this setting. 
• To establish whether quantitation of mitral regurgitation by cardiac magnetic 
resonance was predictive of progression to surgery or symptoms, and assess the 




This work was undertaken to test the following hypotheses: 
• An increasing prevalence of VHD would be associated with increasing age 
• Screening for VHD in patients aged ≥65 years would not be associated with 
significant anxiety. 
• Echocardiography to screen for VHD in the study population would be an 
acceptable tool. 
• Quantitative assessment of mitral regurgitation by cardiac magnetic resonance will 
be predictive of progression to symptoms or surgery. 
• Cardiac magnetic resonance quantitation of mitral regurgitation is comparable to 
echocardiographic quantitation using the PISA method. 
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Chapter 2: The OxVALVE 
Valvular Heart Disease 
Population Cohort Study: 
Development and Methods 
2.1 Overview 
The OxVALVE Valvular Heart Disease Population Cohort Study (OxVALVE PCS) 
was established as a prospective cohort study to examine the prevalence, incidence 
and outcomes of participants aged 65 years and above with newly diagnosed valvular 
heart disease (VHD) in the Oxfordshire population. In addition, developing a well-
characterised and annotated database of a large number of cases of VHD, including 
the full variety of types and severity, is intended to allow the identification of 
suitable populations for future research studies, including pharmacological, surgical 
and percutaneous interventions, the use of novel imaging techniques and devices, and 
even genetic associations. Recruitment began in 2009 and is expected to continue 
until 2015. The data presented in this thesis are from the first 2500 participants 
recruited to the study, and focus on the initial findings of the cross-sectional study. 
As I dedicated a significant amount of time to the setup of the study during my 
period of research, this chapter describes my involvement in the study development, 
followed by a description of the study methods. 
2.2 Study setup and design 
OxVALVE PCS was established as a collaboration between Oxford National 
Institute of Health Research (NIHR) Biomedical Research Centre (BRC), within 
Oxford University Hospitals NHS Trust, and the NIHR School for Primary Care 
Research, within the University of Oxford. Funding support was provided by NIHR 
BRC, and the NIHR Thames Valley Comprehensive Local Research Network 
(TVCLRN). As the inaugural research fellow for the study, I was involved in: 
• initial study meetings and design 
  MD Thesis: Joanna d’Arcy 
  51 
• development of the study protocol 
• design of study documentation  
• liaison with primary care sites 
• procurement of study equipment  
• recruitment and initial training and management of members of the study team  
• sourcing of data collection and storage solutions  
• enrolment and scanning of the initial tranche of study participants  
2.3 Initial study meetings and development of 
study design 
2.3.1 Initial study meetings 
The concept of OxVALVE involved members of each of the stakeholder groups, 
spanning primary and secondary care, with input from clinical and research 
personnel. Meetings to consider the design of the study, what resources would be 
required to establish and roll out the study, and which primary care sites might be 
used initially, were attended by members of Oxford BRC, NIHR School of Primary 
Healthcare Research, and primary care clinicians with involvement in the community 
echocardiography programme in Oxfordshire, as well as myself as the anticipated 
inaugural research fellow.  
2.3.2 Study design and design of the study documentation 
The study design and methods of OxVALVE PCS are fully discussed in in section 
2.4. The study design was developed by a group of collaborators from the various 
stakeholder groups, with consideration being given to identification of potential 
participants, location and logistical support for the main study visit, maximising 
uptake by participants, obtaining an optimal dataset, use of questionnaires, feasibility 
of electrocardiography (ECG) and blood sampling in primary care, and equipment 
used for each part of the study. As the study design evolved, a study protocol was 
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developed in order to meet the study objectives, within the logistical and funding 
constraints identified by the collaborators.  
Study documentation was carefully formulated, with close liaison with primary care 
colleagues, as well as cardiologists. The Patient Information Leaflet (PIL) was 
composed on a background of potential participants receiving it without prior 
knowledge of the study. The PIL needed to be comprehensive enough to provide all 
necessary information, without overwhelming the recipient. This required close 
liaison with, and feedback from, general practitioners (GPs) in order to achieve an 
optimal balance.  
Consent forms were developed to enable participants to give consent at various 
levels, according to participant choice. A minimum level of consent was required to 
allow participants to enrol in the study. The possibility of concern about the storage 
of blood samples, including deoxyribonucleic acid (DNA), and subsequent follow-up 
of participants with morbidity and mortality statistics, necessitated a second level of 
consent which was not mandatory in order to participate in the study. Consent forms 
were therefore carefully formulated to ensure that participants could clearly 
understand and indicate their levels of participation in the study. 
Results letters to GPs were also required, according to whether participants were 
found to have an unremarkable (“normal”) echocardiogram, VHD (including an 
indication of severity and the need for clinical referral to arrange follow up), or 
whether another cardiac abnormality had been detected, which might require further 
assessment and investigation if it was previously unknown. The study team was 
sensitive to the fact that participants might be attending the study visit without a 
cardiovascular diagnosis, but might acquire one as a result of their participation. This 
had the potential to cause significant levels of anxiety, and therefore results needed 
to be dealt with sensitively, and communicated to the primary care team in a timely 
manner, facilitating referral and follow up in secondary care when appropriate. 
An information leaflet on VHD was formulated and given to participants who 
received a new diagnosis of VHD at the end of their study visit. This was intended to 
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provide some information on VHD, including what the implications of a diagnosis of 
VHD might have for the participant, and what the next steps might include. This 
information leaflet provided reassurance to this group of participants, and outlined 
potential sources of further information. 
2.3.3 Liaison with primary care sites 
Potential participants were to be identified from GPs’ patient lists, which needed to 
be done by staff within the GP surgeries, as study staff could not have access to 
identifiable data until participants had given their consent to participate. In order to 
ensure that patients with previously diagnosed VHD were not inadvertently invited to 
participate, a list of relevant diagnostic codes was formulated to allow GP staff to 
identify ineligible patients. This required collaboration with identified members of 
staff within the initial OxVALVE sites, to ensure that potential participants were 
correctly identified, and any inappropriate patients, as judged by GPs in the practices, 
were not sent invitations. Documentation for inviting patients to participate was 
provided by the study to the GP surgery, to be accompanied by a standard covering 
letter from the surgery. 
The main study visit (‘Visit 1’) took place in the GP surgery with which a participant 
was registered. This was felt to be essential in order to maximise patient convenience 
and comfort, with the likely effect of maximising uptake of invitations to participate. 
This also allowed study staff to liaise with GPs to highlight clinical issues.  As the 
initial study visit was in primary care, patients booked appointments with the GP 
surgery directly, in an OxVALVE study ‘clinic’. I formulated the clinic 
requirements, taking into consideration the time required to collect the required data 
without hurrying the participant. The logistical requirements of space, access to 
computer systems when necessary, and administrative support for copying of consent 
forms and reports, were also individual to each participating general practice, and 
liaison with the first GP surgeries to recruit participants was also a part of my role. 
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2.3.4 Study equipment 
As the study was being established de novo, it was necessary to define the equipment 
and resources required for each part of the study. This ranged from administrative 
and stationery needs, to echocardiography equipment, data storage solutions, and 
blood sample processing and storage options. Advice was sought from specialists 
within each of the relevant areas, prior to decisions being made on what equipment, 
supplies or resources were most appropriate to the needs and limitations of the study.  
A fundamental requirement of the study was for appropriate echocardiography 
equipment. In order to decide on the optimal system, taking in to consideration the 
logistical requirements for the unit to be portable and compact, as well as the 
financial constraints, required interaction with industry representatives. In order to 
confirm that the technical requirements of the systems met the study’s needs, I also 
consulted with the senior echo specialist at the John Radcliffe hospital. The relevant 
procurement processes were then followed in order to source the items needed.  
2.3.5 Development of the study team 
In order to deliver a study of the intended scope of OxVALVE PCS, it was necessary 
to recruit a study team to deliver the different aspects of the study.  The initial 
members of the study team were myself, as a research fellow, and a research nurse. 
As the research fellow, I was involved in the recruitment of other study staff, 
including echocardiographers, the study administrator, a clinical support worker, and 
study manager.  
As early team members were recruited to the team, I was involved in ensuring they 
were appropriately orientated with all relevant aspects of the study, undertook ICH 
GCP training, and understood all the relevant aspects of their individual roles. In 
particular, I was involved in introducing echocardiographers to the study sites and 
the primary care staff involved in delivery of OxVALVE within the GP surgeries, as 
well as ensuring that they were all trained in the procedures and standard operating 
procedures (SOPs) relevant to Visit 1. 
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2.3.6 Data collection 
Data entry from paper data collection into electronic databases has the potential for 
significant transcription errors to occur. In order to try and minimise the potential for 
this, we decided to develop electronic case report forms (CRF), which would also 
negate the need for storage of hard copies. Once the required dataset had been 
confirmed, the CRFs were developed in collaboration with IT support. The need for 
data to be captured accurately and concisely directly into a laptop, but without 
disrupting the rapport developed between the member of study staff and the 
participant, required careful consideration of the format of the CRF. The design of 
the CRFs ensured that essential study data had to be input in order to progress 
through the CRF, and for it to be saved. Use was made of drop-down options when 
possible, to facilitate speed of data entry. For certain responses, the answer given 
tailored subsequent questions to ensure that only appropriate questions were asked; 
for example, if a study participant was entered as male, no questions on pregnancy 
were asked.  
The security of identifiable personal data was considered to be of paramount 
importance. To this end, the CRF was developed in such a way that personal 
information, including contact details, was stored separately from the study data. 
Laptops were encrypted in order to ensure the security of data on the CRFs prior to 
the data being uploaded. 
2.3.7 Echocardiographic image and data storage 
The intended number of study participants mandated the provision of significant 
digital storage for echocardiographic images and data. The size of each echo file was 
relatively large, and there was a need to have data backed up to ensure that 
information would not be lost. It was important that solutions put in place at an early 
stage in the study would be future-proof. Discussions on the amount of storage likely 
to be required, and the optimal ways in which this could be sourced and supported 
took place, involving myself as well as representatives from information technology 
and industry. The need for data to be swiftly and safely uploaded, and then easily 
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accessed in future for review of echo studies, were important factors in developing a 
suitable data storage solution for the study’s needs. 
It was vital that echocardiographic data did not get lost between the point of data 
capture, and being uploaded to the storage system. It was not possible to upload 
images directly from the study sites, via a digital link. SOPs were therefore 
developed to ensure that study personnel operating in the GP practices saved data 
securely so that it could be transferred to the server without any loss of information. 
2.3.8 Enrolment and scanning of participants 
Although echocardiographers were to be recruited to the study team, enrolment and 
scanning began before recruitment could be completed. The initial OxVALVE site 
was ready to recruit participants, and therefore I undertook the enrolment and 
echocardiography in the first OxVALVE clinics. This allowed the recruitment of 
study participants to get underway as soon as it was feasible. I also scanned 
participants in the second OxVALVE site to come online, to maximise the 
recruitment rate to the study, and trained new echocardiographers in the completion 
of the study protocol.  
Involvement in the early stages of study recruitment provided the opportunity for any 
problems with aspects of the study visit, the interactions with primary care, and data 
collection and storage to be addressed at the earliest opportunity. 
My involvement in the study extended throughout all aspects of the study, from early 
stages of design and setup, through the establishment of the wider OxVALVE team, 
and including on-site recruitment and echocardiography of study participants. The 
intention was to ensure that the study was set up in such a way at the beginning, that 
it could enrol a large number of participants and collect significant amounts of data 
in the future, without requiring large-scale modifications. It has now enrolled over 
3200 participants at six sites since recruitment began in August 2009 and the 
methodology has now been published. 
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2.4 Methods 
2.4.1 Study setting and participants. 
The OxVALVE Study was carried out in a number of general practices within 
Oxfordshire. The main study visit (visit 1) was held in the general practice where the 
participant was registered. Setting the screening visit in primary care was desirable in 
order to maximise uptake of the invitation to participate in the study. A study visit 
occurring in primary care was also felt less likely to cause significant anxiety 
amongst participants. Clinical data were collated at visit 1, which also allowed 
verification of some details by referring to primary care records when necessary. 
Those participants newly diagnosed with VHD were invited to attend a follow-up 
visit at Oxford University Hospitals NHS Trust, which is a secondary and tertiary 
referral network of hospitals serving the Oxfordshire population, as well as 
surrounding areas. Attendance at the follow-up hospital-based visit allowed more 
sophisticated echocardiography, including three-dimensional imaging when possible, 
as well as 12-lead ECG and blood sampling. The work presented in this thesis relates 
only to the data obtained at visit 1. 
A VHD detection rate of 10% was anticipated, based on data from previous studies. 
These studies however included only valve disease of at least moderate severity. In 
OxVALVE, the threshold for inclusion in the screen-positive group was set 
deliberately low, in order to capture all manifestations of VHD. 
2.4.2 Participant selection and rationale 
Potential study participants were identified from practice lists in the participating 
general practice, and the entire registered population of each participating general 
practice was screened; those aged 65 years old or over, who did not have a 
documented prior diagnosis of VHD, or who were not deemed to meet the exclusion 
criteria as judged by GPs, are invited to participate. Potential participants were 
placed in to a random order, and invited by letter, with a single follow-up reminder to 
  MD Thesis: Joanna d’Arcy 
  58 
non-responders. Those who declined to participate were asked to complete a brief 
response form indicating their reasons for not doing so, in order to detect potential 
sources of study bias. All patient identifiable information was held by the general 
practices until participants consented to participate in the study; no telephone contact 
prior to enrolment in the study was permitted by the Research Ethics Committee. 
The rationale for selecting these patients for a study of the prevalence of VHD was 
based on available data suggesting that, in a developed country, those aged 65 years 
and above have the highest prevalence of VHD(5, 8). This population group is also 
anticipated to grow in size over the coming decades, and VHD in this age group is 
therefore likely to present an increasing burden on health services. Adults under the 
age of 65 years are also more likely to be in employment, and therefore unable or 
unwilling to attend a study visit, which would adversely affect the uptake of the 
study, making it more difficult to draw significant conclusions from the study 
findings.  
Approximately 6,250 patients registered with participating GPs will be invited to 
participate in the study, with recruitment continuing at the time of writing. An uptake 
rate of 80% was targeted in the initial sample predictions; this was based on uptake 
rates from community heart failure screening programmes(205). The sample size was 
chosen in order to yield an anticipated 500 new cases of VHD, assuming a 10% 
detection rate of VHD. The resultant cases of VHD allowed prevalence of undetected 
VHD to be estimated, and demonstrated the patterns of valve lesions and their 
severity. 
2.4.3 Participant recruitment, inclusion and exclusion criteria 
Registered patients of participating general practices were prospectively recruited 
from August 2009, in five general practices within Oxfordshire, according to pre-
specified inclusion criteria. Data presented herein are from the first 2500 participants 
recruited, up to January 2013. Each participant gave written informed consent to be 
involved. 
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Subjects were eligible for inclusion in the study if they met the following  criteria: 
• Aged 65 years or older on the date of the first study visit 
• Male or female 
• Willing and able to give informed consent to participate in the study 
• No documented prior diagnosis of VHD 
Subjects were excluded from the study if any of the following applied: 
• A previous recorded diagnosis of VHD in primary care, identified using relevant 
diagnostic codes. 
• Terminal illness 
• Immobility or general frailty, as judged by the GPs 
• Inability or unwillingness to provide informed consent to participate in the study. 
Potential symptoms of VHD were not included as an exclusion criterion. The 
symptoms of valve disease are non-specific, and have other causes, both cardiac and 
non-cardiac. Chest pain and breathlessness may be due to chest pathology, and pre-
syncope may be due to arrhythmia rather than valve disease. In order to use them as 
an exclusion criterion, these potential symptoms would have had to be coded for 
consistently on general practice systems. This was felt to be unlikely following 
consultation with the primary care-based collaborators. Therefore it was decided not 
to include possible symptoms of VHD in the exclusion criteria to ensure that patients 
were not inconsistently excluded from invitation, and to avoid excluding those with 
symptoms due to non-VHD causes. 
2.5 Clinical assessment 
Participants attended a dedicated research clinic at their registered general practice, 
were they were assessed by an investigating clinician or a sonographer. All study 
staff were trained in Good Clinical Practice (GCP), according to International 
Conference on Harmonisation (ICH) standards. Participants completed an eligibility 
check, and provided informed consent. Consent could be given at various levels, 
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according to whether participants wished to give blood samples for storage and DNA 
testing.  
As well as recording baseline demographic information, assessment at the study visit 
included documenting the following: 
• Cardiovascular history 
• A list of current medications, with specific reference to cardiac medication 
• A smoking history, according to whether the participant has never smoked, or is a 
current or ex-smoker 
• Severity of dyspnoea, according to the New York Heart Association (NYHA) 
classification 
• The presence or absence of chest pain, in accordance with the Canadian Cardiac 
Society (CCS) score 
A focussed physical examination was performed, including:  
• Pulse rate and regularity, 
• Blood pressure, using an automated sphygmomanometer (Omron M6 blood 
pressure monitor, Kyoto, Japan)  
• height (cm) and weight (kg) 
• presence or absence of ankle oedema.  
Clinical data were collated using OpenClinica open source software V3.0.4.1 
(OpenClinica LLC, Waltham, Massachusetts, USA).  
Auscultation was not included in the study visit.  This was based on two main 
factors. The first consideration was that the intention was for the study clinics were 
to be delivered by sonographers, who would be inexperienced at auscultation. It is 
recognised that the sensitivity of auscultation for the detection of VHD is limited: 
Roldan et al reported a sensitivity of only 70% even  when performed by a 
cardiologist(29). Amongst primary care practitioners, auscultation has been shown to 
be even less reliable(30). Echocardiography however has been demonstrated to 
improve detection of valve disease(6, 206). Therefore the addition of auscultation by 
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research sonographers inexperienced in its use was felt not to add sufficient benefit 
to the study visit. 
A transthoracic echocardiogram was then performed, as described below, in section 
5. Participants who were found to be in an irregular heart rhythm had a 12-lead 
electrocardiogram performed. 
At the end of the study visit, participants completed study questionnaires. 
2.6 Echocardiography 
2.6.1 Rationale for using echocardiography 
Transthoracic echocardiography remains the gold standard investigation for patients 
with valvular heart disease, and has been used in epidemiological and outcome 
studies of VHD(8, 12, 65, 207-209).  
 
Limitations of echocardiography include difficulty in obtaining adequate imaging 
quality in some cases due to poor acoustic windows, which may lead to difficulties in 
assessment of the left ventricle (LV), and cardiac valves. Misalignment of the 
Doppler beam may result in underestimation of trans-valvular flow, particularly 
across the aortic valve(210).  
2.6.2 Echocardiography scan protocol 
Comprehensive transthoracic echocardiography was performed by sonographers 
accredited by the British Society of Echocardiography, using a GE Vivid Q machine 
(GE Healthcare, Waukesha, WI, USA), equipped with a 2.0-5.0 MHz transducer. 
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A full echo study was performed according to the British Society of 
Echocardiography (BSE) Guidelines for Transthoracic Minimum Dataset(211). In 
addition, the following images and measurements were obtained: 
• Zoomed images of the aortic valve, aortic root, and proximal ascending aorta, in 
the parasternal long and short axis views 
• Diastolic function assessment, including pulsed wave (PW) Doppler of the mitral 
valve inflow, pulmonary vein flow, and tissue Doppler imaging (TDI) of the septal 
and lateral walls 
• Continuous wave (CW) Doppler through the aortic, mitral, and tricuspid valves to 
demonstrate the presence of regurgitation, in the apical two-, three-, four- or five-
chamber views according to the valve being interrogated. 
In the presence of normal left ventricular systolic function, the left ventricular 
ejection fraction (EF) was assessed by the Teichholz equation, alongside visual 
assessment of overall systolic function. The Teichholz method has been shown to be 
reliable in this context(212), as has visual assessment by experienced personnel(213). 
When quantified visually, ejection fraction was classified as follows: 
• ≥60%: Normal 
• 45-59%: Mild impairment 
• 35-44%: Moderate impairment 
• <35%: Severe impairment 
If systolic function was abnormal on visual assessment, a formal assessment of 
ejection fraction was performed using biplane volumetric assessment, by Simpson’s 
Method of Discs. EF was quantified for the purposes of providing a clinical report to 
the participant’s general practitioner, but was not used as a categorical 
preserved/reduced variable for the analysis of the cohort data. 
2.6.3 Diagnosis of VHD 
During echocardiography, anatomical and physiological assessment of valvular 
function was performed, according to BSE criteria for assessment of valvular 
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stenosis and regurgitation(35). Any left-sided VHD, with the exception of 
‘physiological’ regurgitation, was considered significant. Right-sided valvular 
regurgitation was only considered to be significant if it was of at least moderate 
severity, and any degree of right-sided valvular stenosis was considered significant. 
Therefore, patients were considered ‘screen positive’, i.e. to have a new diagnosis of 
VHD, if they were found to have any of the following: 
• Aortic sclerosis  
• Aortic or mitral stenosis or regurgitation of mild, or greater, severity 
• Pulmonary or tricuspid stenosis of mild, or greater, severity 
• Pulmonary or tricuspid regurgitation of at least moderate severity 
Aortic sclerosis was deemed to be present if assessment of the aortic valve detected 
all of the following: 
• focal areas of thickening and calcification of the valve cusps 
• normal or near-normal cusp mobility 
• maximum transvalvular velocity ≤ 2.5 m/s 
This definition was based on those used in other studies of aortic sclerosis. Focal 
areas of thickening and/or calcification with preserved leaflet mobility has been the 
most consistent descriptor of sclerosis used in these studies(48, 214-217). Not all 
studies of aortic sclerosis have reported velocities across the aortic valve. In those 
studies which have used a defined cut-off, the velocity has variously been 
>1.5m/s(218), 2.0m/s(216, 217), or 2.5m/s(48). The cut-off value of 2.5m/s was 
chosen to dovetail with the velocity of mild aortic stenosis detailed in the guidelines. 
Valvular regurgitation was defined as mild, rather than ‘physiological’ or ‘trivial’ , if 
the regurgitant jet was visible in more than one view on colour flow mapping (CFM), 
and the jet had a clear origin. If valvular anatomy was normal, and the regurgitant jet 
extended <1cm into the left atrium, regurgitation was considered to be 
‘physiological’ or ‘trivial’, and therefore did not meet the criteria for inclusion in the 
‘screen positive’ group. 
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In order to ensure consistency of reporting of echocardiograms, a rolling review of 
approximately 15% of scans was undertaken. A random sample of scans was re-
reported by a pool of BSE accredited study staff, including sonographers and 
physicians.  
2.7 Questionnaires 
Questionnaires were completed by participants at the end of their study visit; these 
included the short form of the Speilberger State-Trait Anxiety Inventory 
(STAI)(219), as well as questions related to participants’ impressions of screening 
for VHD. The questionnaires and the rationale for their use is discussed in chapter 4. 
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Chapter 3: OxVALVE PCS 
Echocardiographic Results 
3.1 Introduction 
In this chapter, the echocardiographic findings of the OxVALVE Population Cohort 
Study will be discussed. Although other studies have attempted to describe the 
prevalence of VHD within different populations, OxVALVE is the first 
comprehensive, prospective community-based study of left- and right-sided VHD, 
including milder forms.  
3.2 Methods 
As described in chapter 2, 2500 participants, aged over 65 years and with no 
previous diagnosis of VHD, were recruited from participating GP surgeries in 
Oxfordshire, between August 2009 and January 2013. In summary, participants 
attended a study visit in their GP surgery, at which detailed demographics, current 
health status, and symptomatic status were recorded. A focussed clinical examination 
was performed, before participants underwent a detailed trans-thoracic 
echocardiogram.  
A low threshold was defined for inclusion in the screen positive group, with any left-
sided valve disease considered to be VHD (except for “physiological” regurgitation), 
and any right-sided stenosis was considered significant. Right-sided regurgitation 
was only counted as VHD if it was moderate or greater in severity. Calcific aortic 
valve disease included the full spectrum of disease, from aortic sclerosis (based on 
the EAE/ASE guidelines(34)) to aortic stenosis (if the maximum transvalvular 
velocity was ≥2.5m/s). 
At the time of data analysis, recruitment was still ongoing into the OxVALVE Study, 
as ethical approval included recruitment of up to 5000 participants. An interim 
analysis was performed when 2,500 participants had been recruited. This allowed an 
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assessment of the breadth of recruitment across age and gender, as well as ethnic 
groups, to guide future recruitment and targeting of study sites. The analysis at 2,500 
was not pre-specified at the outset of the study, but was undertaken when future 
study sites were being considered. The data for those 2,500 participants are presented 
here. 
3.3 Statistical analysis 
Participants were stratified by age and gender to explore the prevalence of VHD in 
the study population, and by the presence or absence of VHD to examine the 
demographic and clinical characteristics. Descriptive statistics are presented using 
means and standard deviations (SD) for continuous variables and counts 
(percentages) for categorical variables. Student’s t-test and Chi-squared test or 
Fisher’s exact test were used to explore dependencies between valve disease and 
quantitative and categorical variables, respectively. Trends across age groups were 
examined using the Chi-squared test for trend. Logistic regression models were used 
to assess the association of the presence of valve disease with demographic and 
clinical characteristics.  All results are expressed as odds ratios (ORs) with 95% 
confidence intervals (CIs), with a 2-tailed p-value <0.05 considered significant. 
3.4 Recruitment 
Results for recruitment are based on the first general practice to complete recruiting 
from their eligible population, and are presented in figure 3.1. From the practice 
patient database, 2281 patients aged 65 years or older were identified, of which 365 
were excluded on the basis of their clinical records; 38% of these were excluded due 
to having previously diagnosed VHD. Invitations were sent to the remaining 1916 
eligible patients, which resulted in a response rate of 52%. There was no response to 
the invitation to participate from 664 patients (35%), with an additional 11% (208 
patients) replying to decline the invitation. Reasons giving for declining to 
participate were most commonly not wishing to travel to secondary care for a follow 
up visit if screen positive (although this was stated as being an optional aspect of the 
study), or having other health problems.  
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3.5 Study population 
The demographic data for the first 2500 participants enrolled in the study are 
presented in Table 3.1 The mean age of participants was 73.0 years (range: 65-95; 
SD: 6.0), and just over half the participants were female (51.5%); 98.8% of 
participants classified their ethnic background as White.  
  
Figure 3.1 Flow chart for first general practice to complete recruitment 
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Table 3.1 Patient Demographics 
Participant Characteristics (N=2500)   N         (%) 
Gender    
Male 1212   (48.48) 
Female 1288   (51.52) 
Age Bands, yrs  
65-69 894    (35.76) 
70-74 727    (29.08) 
75-79 488    (19.52) 
80-84 256    (10.24) 
85-95 135    (5.4) 
Body Mass Index   
BMI <25 778    (31.12) 
BMI 25-30 1054  (42.16) 
BMI >30 668    (26.72) 
Smoking Status  
Non-smoker 1232   (49.28) 
Current smoker 174     (6.96) 
Ex-smoker 1094   (43.76) 
 
3.6 Health and symptom status 
Information regarding health status, including significant past cardiovascular history 
and drug history, and data on current symptom status was available for all 
participants, and data are shown in Table 3.2. The most commonly reported 
cardiovascular conditions were hypertension (44.9%) and hyperlipidaemia (35.7%). 
Diabetes mellitus was reported by 11.3% of participants, with only 1.8% reporting a 
known history of rheumatic fever. Only 109 participants (4.4%) reported a history of 
atrial fibrillation. On questioning about symptom status, only 64 participants (2.6%) 
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described NYHA class III/IV symptoms, and only 5.16% had a CCS score of 1 or 
more. 
Table 3.2 Health and symptom status 
History 
Diabetes mellitus 282     (11.3%) 
Hypertension 1123   (44.9%) 
Hyperlipidaemia 892     (35.7%) 
Atrial fibrillation 109     (4.4%) 
Myocardial infarction 131     (5.2%) 
Coronary angiography 224     (9.0%) 
Percutaneous coronary intervention 97       (3.9%) 
Coronary artery bypass grafting 47       (1.9%) 
Angina 213     (8.5%) 
Stroke/TIA 155     (6.2%) 
Rheumatic fever 45       (1.8%) 
Pacemaker 14       (0.6%) 
NYHA Class 
NYHA I/II 2436   (97.4%) 
NYHA III/IV 64       (2.6%) 
CCS Score 
0 2371   (94.8%) 
I/II 120     (4.8%) 
III/IV 9         (0.4%) 
All values are expressed as numbers (%) for presence of variable 
TIA: Transient ischaemic attack; NYHA: New York Heart Association; CCS: Canadian 
Cardiovascular Society 
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3.7 Medication and examination findings 
Current drug histories were obtained from all participants, although data regarding 
blood pressure were unavailable on 5 participants, as a result of the machine being 
unable to obtain a measurement. Data on medication and examination findings are 
shown in Table 3.3. 
Table 3.3 Medication and examination findings 
Medication 
Lipid lowering agent 948    (37.9%) 
ACEi 579    (23.2%) 
ARB 262    (10.5%) 
Anticoagulant 65      (2.6%) 
Aspirin 541    (21.6%) 
Beta blocker 390    (15.6%) 
Calcium channel blocker 380    (15.2%) 
Diuretic 451    (18.0%) 
Nitrates 133    (5.3%) 
Other anti-platelet 35      (1.4%) 
Examination findings  
Heart rate (bpm) 72.8   (11.8) 
Systolic blood pressure (mmHg) 140    (19.4) 
Diastolic blood pressure (mmHg) 79.5   (11.3) 
Ankle oedema 305    (12.2%) 
Body mass index (kg/m2) 27.6   (5.0) 
Sinus rhythm 2408  (96.3%) 
Atrial fibrillation 83      (3.3%) 
Paced rhythm 9        (0.4%) 
All values are expressed as numbers (%) for presence of the variable, or mean±SD 
ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker;  
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3.8 Echocardiographic findings 
All participants underwent transthoracic echocardiography, although difficulty 
obtaining diagnostic images in a proportion of participants resulted in some data 
points being unavailable (less than 25/1% for the majority of structures or 
measurements). Reasons for inability to obtain diagnostic images include: co-
existing pulmonary disease, obesity, and a large left-sided pleural effusion. A full 
BSE dataset(211) was obtained, with 2D, Doppler, colour flow mapping and M-
mode measurements included. Assessment of valvular function, and quantification of 
valve lesions was undertaken according to BSE guidelines for the assessment of 
VHD(35). Data relating to ejection fraction, septal thickness, left ventricular end 
diastolic dimension, left atrial dimension, and left ventricular mass and mass index 
are shown in table 3.4. 
Table 3.4 Echocardiographic findings 
Ejection fraction (%) 67.2     (8.7) 
IVSd (mm) 10.0     (2.3) 
LVEDd (mm) 46.0     (7.2) 
LA diameter (mm) 37.0     (6.5) 
LV mass (g) 154.5   (53.2) 
LV mass index (g/m2) 81.8     (25.3) 
Total number of participants analysed for these variables was between 2478 and 2485;  
All values are presented as mean±SD;  
IVSd: inter-ventricular septal thickness in diastole; LVEDd: left ventricular end diastolic 
dimension; LA: left atrium; LV mass: left ventricular mass; LV mass index: left ventricular 
mass indexed to body surface area 
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3.9 Prevalence of newly diagnosed valvular 
heart disease 
Some form of valvular heart disease was diagnosed in just over half of the 
participants (50.8%), according to the study criteria described in chapter 2. The 
majority of newly diagnosed VHD was mild in severity, although in 159 participants 
(6.4%) new VHD of moderate or greater severity was detected. Aortic sclerosis was 
the most common new diagnosis, affecting 34% of the cohort. Mitral regurgitation 
was diagnosed in 22.1% of the cohort (19.8% mild MR, 2.3% moderate or severe 
MR), and aortic regurgitation was detected in 15.2% of participants (13.6% mild AR, 
1.6% moderate or severe AR); 32 participants (1.3%) were found to have previously 
undiagnosed aortic stenosis, of which 17 (0.7%) had AS that was moderate or severe.  
Bicuspid aortic valve was detected in 8 participants (0.3%). Mitral stenosis was 
detected in only 9 participants (0.4%). Right-sided valve disease was uncommon in 
study participants, with tricuspid regurgitation being the most common (2.7% 
moderate TR); no tricuspid or pulmonary stenosis was detected. Table 3.5 shows 
data for the prevalence of newly diagnosed VHD in this cohort. 
 
 
Table 3.5 Prevalence of newly diagnosed valvular heart disease 
Any form of VHD 
None 1231    (49.2) 
Mild 1110     (44.4) 
Moderate/Severe 159       (6.4) 
 
Aortic Sclerosis 
None 1649     (66.0) 
Mild 795       (31.8) 
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Table 3.5 Prevalence of newly diagnosed valvular heart disease 
Moderate 51         (2.0) 
Severe 5           (0.2) 
Aortic Stenosis 
None 2468    (98.7) 
Mild 15        (0.6) 
Moderate 13        (0.5) 
Severe 4          (0.2) 
Aortic Regurgitation 
None 2118    (84.7) 
Mild 341      (13.6) 
Moderate 40       (1.6) 
Severe 1         (0.04) 
Bicuspid Aortic Valve 
No 2492    (99.7) 
Yes 8           (0.3) 
Mitral Stenosis 
None 2491   (99.6) 
Mild 7          (0.3) 
Moderate-severe 2          (0.1) 
Mitral Regurgitation 
None 1948    (77.9) 
Mild 494      (19.8) 
Moderate 55         (2.2) 
Severe 3           (0.1) 
Tricuspid Regurgitation 
None 1429     (57.3) 
Mild 599       (24.0) 
Moderate 67         (2.7) 
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Table 3.5 Prevalence of newly diagnosed valvular heart disease 
Pulmonary Regurgitation 
None 1932      (77.3) 
Mild 561        (22.4) 
Moderate 7            (0.3) 
All values are presented as numbers (%) for the variable 
 
More than one valve lesion was detected in 38.5% of participants. This was most 
common in aortic regurgitation, in which 81% had at least one other form of VHD. 
Over half of those with mitral regurgitation (58%), and 47% of those with AoScl also 
had at least one other valve lesion found.  
3.10 Associations with newly diagnosed 
valvular heart disease 
Univariate analysis was performed to look at associations with a new diagnosis of 
VHD. As expected, increasing age was significantly associated with a new diagnosis 
of VHD. In the youngest age band 42.4% of participants were screen positive, but 
over three quarters (76.3%) of those aged 85-95 years were found to be so. 
Increasing age was also associated with an increased likelihood of moderate or more 
VHD. This association held true for all forms of VHD detected, with the exception of 
PR due to the small number of participants with significant PR. These associations 
are shown in Table 3.6 and Figure 3.2 (data for MS and PR are not included due to 
the small numbers). 
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Table 3.6 Association of age with prevalence and severity of VHD 
Age bands 65-69 70-74 75-79 80-84 85-95  
n 894 727 488 256 135  
Any VHD, % 42.4 45.8 57.4 68.0 76.3 p<0.001 
Moderate/Severe VHD, % 2.5 4.4 7.8 13.7 23.7 p<0.001 
Moderate/Severe MR, % 1.0 1.7 3.3 4.7 6.7 p<0.001 
Moderate/Severe AS, % 0.3 0.7 0.0 1.6 3.7 p<0.001 


























Figure 3.2 Prevalence of any VHD, MR, AS, AoScl, AR and TR by age 
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Data relating to associations of new diagnosis of VHD with other demographics and 
health status are presented in table 3.7. On univariate analysis, a significantly greater 
likelihood of a new diagnosis of VHD was associated with a history of hypertension, 
hyperlipidaemia, AF, MI, coronary angiography, CABG, and stroke/TIA. There was 
no association with gender, diabetes mellitus, percutaneous coronary intervention or 
angina. 
Table 3.7 Association of demographics and health status with newly diagnosed 
VHD 
 No VHD VHD p-value 
Gender 
Males 612     (50.5%) 600     (49.5%)  
Females 619     (48.1%) 669     (51.9%) 0.239 
Smoking status 
Non-smoker 586     (47.6%) 646     (52.4%)  
Current smoker 101     (58.0%) 73       (42.0%)  
Ex-smoker 544     (49.7%) 550     (50.3%) 0.032 
HIstory 
Diabetes mellitus 143     (50.7%) 139     (49.3%) 0.645 
Hypertension 508     (45.2%) 615     (54.8%) <0.001 
Hyperlipidaemia 413     (46.3%) 479     (53.7%) 0.032 
Atrial fibrillation 35       (32.1%) 74       (67.9%) <0.001 
Myocardial Infarction 51       (38.9%) 80       (61.1%) 0.02 
Coronary angiography 86       (38.4%) 138     (61.6%) <0.001 
Percutaneous coronary 
intervention 
42       (43.3%) 55       (56.7%) 0.276 
CABG 15       (31.9%) 32       (68.1%) 0.024 
Angina 101     (47.4%) 112     (52.6%) 0.628 
Stroke/TIA 60       (38.7%) 95       (61.3%) 0.009 
Rheumatic fever 20       (44.4%) 25     (55.6%) 0.618 
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Table 3.7 Association of demographics and health status with newly diagnosed 
VHD 
NYHA Class 
I/II 1196    (49.1%) 1240    (50.9%)  
III/IV 64       (54.7%) 29       (45.3%) 0.449 
All values are expressed as numbers (%); p-value <0.05 was considered significant 
TIA: Transient ischaemic attack; NYHA: New York Heart Association; CABG: Coronary 
Artery Bypass Graft 
 
A multiple regression analysis was performed to look at factors associated with any 
valvular heart disease, the results of which are shown in Table 3.8. Increasing age, 
female gender, previous angiography, systolic blood pressure and atrial fibrillation 
were all associated with an increased likelihood of VHD, as were increased septal 
thickness, increasing left ventricular mass and mass index, and increased left 
ventricular diameter. A history of angina, and a higher heart rate, higher diastolic 
blood pressure and presence of ankle oedema on clinical examination were 
associated with a reduced likelihood of a new diagnosis of VHD. 
Table 3.8 Regression analysis for a new diagnosis of VHD 
 OR 95% CI p-value 
Age, yrs 1.39 (1.29,1.50) <0.001 
Female gender 1.60 (1.33,1.92) <0.001 
History 
Angina 0.58 (0.40,0.83) 0.003 
Coronary angiography 1.69 (1.18,2.41) 0.004 
Examination findings 
Heart rate, bpm 0.85 (0.79,0.92) <0.001 
Systolic blood pressure, mmHg 1.11 (1.05,1.18) <0.001 
Diastolic blood pressure, mmHg 0.88 (0.80,0.97) 0.010 
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Table 3.8 Regression analysis for a new diagnosis of VHD 
Ankle oedema 0.66 (0.51,0.86) 0.002 
Atrial fibrillation 2.59 (1.52,4.42) <0.001 
Echocardiographic findings 
IVSd, mm 1.10 (1.06,1.14) <0.001 
LVEDd, mm 1.03 (1.02,1.05) <0.001 
LV mass, g 16.3* (12.4,20.2) <0.001 
LV mass index, g/m2 9.5* (7.6,11.5) <0.001 
Results are presented as odds ratios (OR), with the corresponding 95% confidence 
interval (CI); p-value <0.05 was considered significant 
OR for age is per 5 yrs increase; OR for heart rate is per 10bpm increase; OR for 
blood pressure is per 10mmHg increase; OR for IVSd and LVEDd is per mm increase 
IVSd: Inter-ventricular septum, diastole; LVIDd: left ventricular end diastolic 
dimension; LV mass: left ventricular mass; LV mass index: left ventricular mass 
indexed to body surface area; * Denotes Effect size rather than OR, due to continuous 
nature of the variable 
 
3.11 Associations with individual left-sided 
valve lesions 
Multiple regression analysis was performed for each valve lesion. Due to the small 
numbers of right-sided VHD and mitral stenosis, data are only presented for aortic 
valve lesions and mitral regurgitation. All individual lesions were associated with 
increasing age, as shown below in the tables relating to individual lesions. 
3.11.1 Associations with mitral regurgitation 
Mitral regurgitation was associated with an increased likelihood of female gender 
(OR: 1.68; 95%CI: 1.24-2.27; p=0.001). It was also strongly associated with an 
increased likelihood of atrial fibrillation (OR:3.49; 95% CI: 2.03-5.97; p<0.001).  
Analysis of echocardiographic findings demonstrated an association between 
increasing left atrial size, increasing septal thickness, increasing left ventricular size, 
and increasing left ventricular mass and mass index. MR was also associated  with 
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increasing LV mass and mass index when stratified by severity, looking at mild MR 
or moderate & severe MR. Unexpectedly, current smoking status was associated with 
a lower likelihood of mitral regurgitation, as was increasing body mass index. A 
lower likelihood of MR in those who were ex-smokers did not reach statistical 
significance. 
Table 3.9 Regression analysis for associations with mitral regurgitation 
N=2461 OR 95% CI p-value 
Age, yrs 1.03 (1.01,1.05) 0.001 
Female gender 1.68 (1.24,2.27) 0.001 
Smoking status 
Current smoker 0.58 (0.36,0.92) 0.021 
Ex-smoker 0.80 (0.65,1.00) 0.052 
Examination findings 
Atrial fibrillation 3.49 (2.03,5.97) <0.001 
BMI, kg/m2 0.90 (0.87,0.92) <0.001 
Echocardiographic findings 
LA size, cm 1.36 (1.13,1.64) 0.001 
IVSd, cm 2.05 (1.25,3.34) 0.004 
LVEDd, cm 1.70 (1.44,2.00) <0.001 
LV mass, g (mild MR) 13.7* (8.8,18.6) <0.001 
LV mass, g (moderate/severe MR) 15.8* (2.8,28.8) 0.02 
LV mass index, g/m2 (mild MR) 9.5* (7.13,12.0) <0.001 
LV mass index, g/m2 (moderate/severe MR) 13.5* (7.1,19.9) <0.001 
Results are presented as odds ratios (OR), with the corresponding 95% confidence 
interval (CI); p-value <0.05 was considered significant 
OR for age is per 5 yrs increase; OR for IVSd and LVEDd is per cm increase IVSd: Inter-
ventricular septum, diastole; LVEDd: left ventricular end diastolic dimension; LA: left 
atrium; BMI: Body Mass Index; LV mass: left ventricular mass; LV mass index: left 
ventricular mass indexed to body surface area; * Denotes effect size rather than OR, due 
to continuous nature of the variable 
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3.11.2 Associations with aortic regurgitation 
In aortic regurgitation, multiple regression analysis demonstrated an increase in 
likelihood of AR with increasing LV size. There was also a  significant association 
between a new diagnosis of AR and increasing LV mass and mass index. This 
association was more pronounced when the LV mass was examined in the presence 
of moderate or severe AR. A new diagnosis of AR was less likely in those who were 
ex-smokers, but this did not reach statistical significance in those who were current 
smokers. Gender was not significant for the likelihood of a new diagnosis of AR. 
Table 3.10 Regression analysis for associations with aortic regurgitation 
N=2477 OR 95% CI p-value 
Age, yrs 1.09 (1.07,1.11) <0.001 
Smoking status 
Current smoker 0.77 (0.47,1.26) 0.295 
Ex-smoker 0.76 (0.60,0.96) 0.023 
Echocardiographic findings 
LVEDd, cm 1.17 (1.02,1.35) 0.028 
LV mass, g (mild AR) 7.4* (1.7,13.1) 0.01 
LV mass, g (moderate/severe AR) 43.4* (28.2,58.5) <0.001 
LV mass index, g/m2 (mild AR) 5.2* (2.4,8.1) <0.001 
LV mass index, g/m2 (moderate/severe AR) 26.3* (18.8,33.7) <0.001 
Results are presented as odds ratios (OR), with the corresponding 95% confidence 
interval (CI); p-value <0.05 was considered significant 
OR for age is per 5 yrs increase; OR for LVEDd is per cm increase LVEDd: left ventricular 
end diastolic dimension; LV mass: left ventricular mass; LV mass index: left ventricular 
mass indexed to body surface area; * Denotes Effect size rather than OR, due to 
continuous nature of the variable 
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3.11.3 Associations with aortic stenosis 
Aortic stenosis was only significantly associated with increasing age, a current 
smoking history, and increased left atrial size, when non-significant terms were 
excluded. There was a trend towards a decreased likelihood of aortic stenosis in ex-
smokers, but this did not reach statistical significance. Regression analysis to look 
for an association between a new diagnosis of AS and LV mass also did not reach 
statistical significance; this is likely to be due to the low numbers of participants with 
AS, particularly moderate or severe AS. Increased LA size is linked to AS due to 
increased left-sided filling pressures. 
Table 3.11 Regression analysis for associations with aortic stenosis 
N=2485 OR 95% CI p-value 
Age, yrs 1.09 (1.03,1.15) 0.001 
Smoking status 
Current smoker 3.12 (1.1,8.85) 0.032 
Ex-smoker 0.48 (0.21,1.08) 0.077 
Echocardiographic findings 
LA size, cm 2.27 (1.60,3.23) <0.001 
Results are presented as odds ratios (OR), with the corresponding 95% confidence 
interval (CI); p-value <0.05 was considered significant 
OR for age is per 5 yrs increase; OR for LA size is per cm increase; LA: Left atrium 
 
3.12 Discussion 
The findings of this study demonstrate that: 
1) Valvular heart disease is highly prevalent in those over the age of 65 years, 
although the majority of this is mild. 
2) Increasing age is associated with an increasing prevalence of VHD. 
3) Valvular regurgitation is the most commonly detected form of VHD in the 
community-based population. 
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4) Female gender, lower BMI, and atrial fibrillation are associated with significant 
increased likelihood of mitral regurgitation. 
5) Aortic stenosis, but not other forms of left-sided VHD, is associated with a 
current smoking status. 
6) Mitral and aortic regurgitation are associated with increasing left ventricular 
mass. 
3.12.1 High prevalence of VHD 
This study is the first prospective, community-based study of valvular heart disease 
investigating the prevalence of left- and right-sided VHD, and including the whole 
spectrum of disease. Although previous studies have attempted to ascertain similar 
data, they have been retrospective(8, 9, 16), hospital based(5), focussed on the 
investigation of non-valvular heart disease(18), or only aimed at aortic valve 
disease(9, 16, 20, 41). 
Over half of participants (50.8%) in this study were found to have previously 
undetected VHD, which is higher than in other studies. Nkomo et al(8) report a 
prevalence of 13.2% in those aged over 75, which is much lower than the 63.4% 
detected in the same age group by OxVALVE. However, Nkomo et al excluded 
milder forms of VHD. Within the OxVALVE study, moderate or greater VHD was 
detected in 11.9% of those of the same age, which is comparable to those noted by 
Nkomo, when taking into consideration that OxVALVE excluded those with a 
previous known diagnosis of VHD. However other studies, particularly those looking 
at aortic stenosis, have suggested higher prevalences than this. In a 2013 meta-
analysis looking at aortic stenosis prevalence from the point of view of demand for 
trans-catheter aortic valve implantation, Osnabrugge et al found a prevalence of 
12.4% in those aged ≥75 years, of which 3.4% was characterised as severe(220); the 
Reykjavik-AGES study found similarly high prevalences(20). Differences in 
prevalence between different cohorts are likely to represent different populations 
being studied, and different methods of assessment and grading of severity for aortic 
stenosis. The population studied by OxVALVE were asymptomatic and community-
based, and those with previously detected disease, either due to a murmur being 
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heard or symptoms being investigated, were excluded. Those who were more frail or 
unwell may have chosen not to participate in the study, leading to potential selection 
bias and lower prevalence of significant VHD of all types. 
The finding of moderate or severe VHD in 6.4% of the study population suggests 
that there is a significant burden of undetected clinically relevant VHD in this age 
range. Even in the youngest age group, 2.5% were found to have VHD which was 
graded as moderate or severe. Over the remainder of their life expectancy, this may 
reach criteria for intervention, and should be followed up with this in mind. 
Increasing numbers of interventions for VHD are being carried out even in the oldest 
age groups, with improving outcomes(37), confirming the importance of timely 
detection of VHD in this population. 
Although the majority of VHD detected in this study was mild, when subjects with 
known VHD from the community were included the prevalence of clinically 
significant VHD increased to 11.3%. The protracted and unpredictable nature of 
VHD requires serial testing in order to monitor disease progression and ensure timely 
intervention if required. Monitoring in such large numbers of patients will require 
investment in echocardiographic services and valve clinics, and the costs of this will 
be considerable. However, the costs of appropriate surveillance and intervention may 
be offset by savings in the cost of hospitalisations and treatment for heart failure for 
VHD, as discussed in section 3.12.7. There is also evidence to suggest that over-
investigation of VHD may occur, alongside practices which do not adhere to 
guidelines on the management of VHD(221). This suggests that significant cost 
savings could be made in valve surveillance, as has been demonstrated by Taggu et 
al(222), when services are optimally managed.   
In a publicly funded healthcare system with finite resources, consideration needs to 
be given to which patients are most appropriate to follow up with routine 
surveillance.  Some patients in the oldest age groups may feel that they would not 
wish to have any treatment for VHD if they reached criteria for surgical or 
percutaneous intervention. In these cases where symptoms would be treated 
medically, sensitive discussions between clinical and patient may lead to a decision 
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not to follow up the VHD on a routine basis. These discussions should take place 
between patients and specialists in order to ensure that patients are apprised of all of 
the factors which might influence their decision. Conversely, those who are reluctant 
to consider possible intervention, but who are otherwise suitable candidates for repair 
of replacement of their valve, require a suitable appreciation of  the ramifications of 
not having treatment. 
To provide access to a streamlined service providing appropriate patient evaluation 
and serial testing, ensuring the timely consideration of intervention with prompt 
referral to a surgeon as appropriate, and provide patients with vital education both 
pre- and post-surgery may be best achieved through a specialist valve clinic 
delivered by a multidisciplinary team. This is in keeping with similar models used 
for heart failure, arrhythmias and coronary disease, and is recommended by national 
and international societies(223, 224). Establishing clinics such as these will allow the 
concentration of expertise in VHD, ensuring that training and education are 
optimised and practices are kept up to date. This does not mean that such service 
delivery should be restricted to tertiary centres. A ‘hub and spoke’ model with 
satellite clinics for surveillance having strong links with a specialist centre will 
ensure maximal accessibility to optimal expertise. Accessibility in the older age 
groups is likely to be of particular importance. In individuals who may have other 
comorbidities to take into account when considering intervention, access to those 
with the greatest experience in managing such cases is also of greatest value. 
The potential costs of follow up of large numbers of patients with VHD highlights 
the need for further work on risk factors and markers for more rapid progression, or 
decompensation. The ability to identify those most at risk of rapid progression and 
who will meet indications for intervention for VHD will help to avoid high costs 
associated with management of LV dysfunction, prolonged hospital stays and 
difficult post-operative course. Conversely, the identification of those who are less 
likely to progress to severe disease, symptom development or reaching surgical 
criteria will also facilitate the rationalisation of resource allocation. Less frequent 
follow up in those with a more benign phenotype would result in better use of 
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investigations and out-patient time, as well as freeing the patients from an 
unnecessary frequency of follow up. 
3.12.2 Increasing prevalence with increasing age. 
The strong association of age with prevalence of VHD is in line with those 
demonstrated in previous retrospective studies of VHD(5, 8, 9, 18, 20, 41, 225). This 
association was demonstrable for all valve lesions. Increasing age was also 
associated with an increased likelihood of VHD of greater severity. This is in 
keeping with degenerative disease as the major aetiology of VHD in developed 
countries, as previously demonstrated in the hospital-based Euro Heart Survey(5). 
The AGES-Reykjavik study demonstrated a rapid increase in prevalence of severe 
AS with age, with a prevalence of 0.92% in those aged under 70 years, to 7.3% in 
those ≥80 years of age(20). Using population projections, they suggest that the 
numbers of patients affected by severe AS will triple by 2060. Such a potentially 
large number of patients requiring management of their AS is likely to put a great 
burden on any healthcare system, financially and logistically, and demands in-depth 
planning to avoid being overwhelmed. 
When compared with the wider population, both within Oxfordshire and across 
England and Wales, the study population was younger, with a larger proportion of 
study participants being under the age of 75 than in the general population. Those 
invited to participate in the study who declined to participate were invited to provide 
feedback on reasons for declining. A frequently sited reason for declining to 
participate was being too old, or having other co-morbidities. This was anticipated 
when designing the study information for patients. It was specifically stated that 
participants of all ages would be valuable to the study, and it was also specified that 
the cost of any transport to study appointments could be claimed, including taxis. 
Despite this, some invitees stated that their age and difficulty with travelling to the 
general practice were barriers to participation.  
Increasing age is associated with increased co-morbidities, and this also contributed 
to an overall younger population responding to the study invitation. Census data are 
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gathered without respondents needing to leave their own home, but participation in 
the OxVALVE study required travel and mobility. Some decliners felt that they had 
too many other health problems to feel able to participate in the study, and this is 
likely to have resulted in the proportion of older age groups being smaller than in the 
general population. Prior to study invitation letters being sent out to invitees, primary 
care practitioners also reviewed the list of eligible patients on the practice list. If they 
were aware of any of their patients with significant frailty or co-morbidities, those 
patients were excluded from the invitation process. This is also reflected in the ages 
of those who eventually chose to participate in the study. 
Table 3.12 Comparison of age of OxVALVE participants with Oxfordshire population 
and population of England and Wales 





England and Wales 
65-69 35.8 29.1 29.0 
70-74 29.1 23.4 23.6 
75-79 19.5 19.0 19.3 
80-84 10.2 14.4 14.5 
≥85 5.4 14.2 13.6 
Results are expressed as percentages. N=2500 for OxVALVE participants. 
Data for Oxfordshire population, and population of England and Wales taken from Office of 
National Statistics National Census 2011 data. 
 
If such a high prevalence of VHD is seen within this population, does it in fact 
represent part of the spectrum of ‘normal’? The term ‘degenerative’ has previously 
been widely used to describe some forms of VHD, in particular AS. Recent advances 
in understanding of the underlying processes of VHD have led to this being used less 
commonly. The inflammation demonstrated in AS, leading on to fibrosis and 
calcification, and even subsequent bone formation in very advanced disease, suggest 
that this is a truly pathological process, and far from normal. Such changes are found 
in AS in all age groups, and so cannot be considered a part of the ageing process.  
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The mechanisms underlying aortic and mitral regurgitation are less well elucidated, 
and structural abnormalities are more heterogeneous. Leaflet prolapse, myxomatous 
degeneration of the valve, chordal rupture, or even no clear identifiable cause even 
on pathological examination: any of these may give rise to valvular regurgitation. 
Again, these processes are seen in all age groups. They should not simply be 
attributed to age, or one end of the spectrum of normality. 
3.12.3 High prevalence of valvular regurgitation 
In the OxVALVE cohort, the most commonly detected valve lesions were mitral and 
aortic regurgitation. Although in a hospital-based study, Iung et al found AS to be the 
commonest form of VHD(5), community-based studies have consistently 
demonstrated higher prevalences of mitral and aortic regurgitation(8, 18, 225).  
As part of the Strong Heart Study, Lebowitz et al found AR in 14.4% of participants 
aged >60 years old(18), which is comparable with our detected prevalence of 15.3%. 
Singh et al found a prevalence of approximately 10.8% in those over the age of 
60(225), although with a higher prevalence of moderate or greater severity.  
Jones reports a prevalence of mitral regurgitation of approximately 28% in those 
aged ≥65 years old(19), which is higher than the prevalence detected in our study, 
despite similar echocardiographic criteria. Although ethnic differences might be 
considered to be responsible, the Framingham Heart Study participants are of a 
similar ethnic mix to our study population, but reported a prevalence of MR of 27% . 
in those aged over 60(225). Nkomo reported a prevalence of 7.3% in those aged ≥65 
years of age(8), although this study had a higher threshold for detection of disease. 
A small but significant proportion of the newly diagnosed regurgitation in our cohort 
was of moderate or greater severity (2.3% moderate/severe MR; 1.6% 
moderate/severe AR). This corresponds to the severity of disease found in the Strong 
Heart Study(18, 19), although Singh suggests a similar prevalence of moderate or 
greater aortic regurgitation, and mitral regurgitation in women, but a higher 
prevalence of more severe MR in participants of male gender(225). 
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3.12.4 Female gender, body mass index and atrial fibrillation 
are associated with mitral regurgitation. 
In this study population, multiple regression analysis showed significant associations 
between mitral regurgitation and female gender, body mass index and atrial 
fibrillation.  
Female gender has previously been demonstrated to be associated with an increased 
risk of regurgitant valve disease in only one other epidemiological study of 
VHD(19). Aortic regurgitation has been linked to male gender in participants in the 
Framingham Heart Study(225), but this study showed no gender association with 
mitral regurgitation. Nkomo found that overall VHD was diagnosed less often in 
women in the community-based setting, and this was evident for mitral and aortic 
regurgitation(8). In Great Britain and Ireland, only 30% of those undergoing mitral 
valve repair for degenerative mitral valve disease, and 40% of those undergoing 
mitral valve replacement, are female(37). The discrepancy between these statistics 
and our data would suggest that women may be under-treated for mitral valve 
disease, or may present too late for beneficial intervention. 
Atrial fibrillation resulting from significant mitral regurgitation is thought to relate to 
increased left atrial pressure and stretch. This study also showed a significant 
relationship between left atrial size and mitral regurgitation. In 2004, Parkash et al 
showed a correlation between the risk of onset of atrial fibrillation and left atrial 
size(226), and MR, LA size and onset of AF are clearly inter-related. There is a 
possibility that AF itself results in a type of “functional” MR, which resolves when 
sinus rhythm is restored(227), although it is likely that a much greater proportion of 
MR that co-exists with AF is primary, organic MR. The risk of significant MR 
developing associated atrial fibrillation is approximately 5% per year(228, 229). The 
onset of atrial fibrillation in severe asymptomatic MR is an indication for surgery 
according to current guidelines(230) (Class of recommendation: IIa). There is some 
evidence that atrial fibrillation at the time of intervention is associated with worse 
outcomes(231, 232), although this may be offset by concomitant AF intervention at 
the time of surgery(233). 
  MD Thesis: Joanna d’Arcy 
  89 
The data presented here suggest that in patients with newly-diagnosed AF, 
echocardiography to look for associated valve disease is a worthwhile undertaking. 
This approach is in keeping with international guidelines for the management of 
AF(234, 235). However, the current UK guidelines from the National Institute of 
Health and Care Excellence suggest that routine echocardiography is not 
necessary(236). As stated in Chapter 2, auscultation is unreliable even in relatively 
skilled hands(29, 30), and therefore it cannot be relied upon in isolation to detect 
VHD. Unless echocardiography is routinely performed in those with newly 
diagnosed AF, it is likely that VHD will continue to be missed in a proportion of 
these patients. 
In this population-based screening study for VHD, multiple regression analysis 
demonstrated an association between body mass index and mitral regurgitation (OR 
0.90, 95% CI 0.87,0.92, p<0.001). This suggests that for every unit increase in BMI, 
there is a 10% decrease in the likelihood of a new diagnosis of mitral regurgitation. 
This is consistent with the findings of the other studies on mitral regurgitation 
discussed above(19, 225). The cause for this association remains unclear. 
3.12.5 Aortic stenosis and smoking status. 
Aortic stenosis was the only valve lesion to have a positive correlation with current 
smoking status in the OxVALVE Study. In studies looking at associations with 
regurgitation, there has been no evidence of a positive correlation between either 
aortic regurgitation(225)  or mitral regurgitation(19). However, the link between 
aortic stenosis and smoking has been demonstrated in several previous studies. 
Stewart et al demonstrated a 35% increase in the risk of aortic stenosis in 
smokers(42), and it has also been shown to shown to be associated with calcification 
of the aortic valve, although not with progression of calcification(97).  
Aortic stenosis has been shown to share risk factors with atherosclerotic disease(42),  
and smoking is a well-established risk factor for atherosclerosis. The 
pathophysiological mechanisms underlying AS also resemble those seen in 
atherosclerosis(237). This is results in a high percentage of patients with significant 
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AS having concomitant coronary artery disease (CAD): over half of those over the 
age of 70 in a Scandinavian study(11), and over 40% in those aged 80 or over in a 
British series(238). Despite this close histological and epidemiological relationship, 
medical interventions - most notably statin therapy - have not provided the same 
benefit for the treatment of AS as for CAD(79, 239, 240). 
3.12.6 Left ventricular mass and VHD. 
A diagnosis of aortic or mitral regurgitation was associated with increasing left 
ventricular mass and mass index. Overall a diagnosis of VHD was associated with a 
significantly higher LV mass, although no statistically significant difference was 
found between the LV mass of those with or without AS.  
It would be expected to find a positive correlation between a diagnosis of AS and LV 
mass or mass index. In AS, the decreasing valve area with progressive stenosis 
results in a gradually increasing pressure gradient across the valve. As discussed in 
Chapter 1, the LV hypertrophies in order to normalise afterload. In the OxVALVE 
study however, there was no statistically significant association between a diagnosis 
of AS of any severity and LV mass or mass index. This is a result of having small 
numbers of participants in the study who were found to have aortic stenosis. Only 32 
participants (1.3%) were diagnosed with aortic stenosis in the study, of which nearly 
half were mild AS.  
The data presented here demonstrate a significant association between a diagnosis of 
aortic regurgitation and LV mass and mass index. Eccentric and concentric 
hypertrophy occur in AR along with LV dilatation, to support an increase in total 
stroke volume from the LV(111, 112). The OxVALVE data also demonstrate that 
LV mass index increase with increasing severity of AR. This agrees with data from 
Padial et al, who demonstrated the greatest increases in LV mass in those with more 
severe AR(110). An increase in left ventricular mass has also been shown to be 
associated with poorer surgical outcomes in those with AR(241). 
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In mitral regurgitation, left ventricular dilatation occurs to compensate for the 
increased loading of the left ventricle. This dilatation results from addition of 
sarcomeres as well as their rearrangement(141, 142), resulting in increased left 
ventricular mass. The finding of increased LV mass in MR of all levels of severity 
suggests that this compensation may begin at an early stage of valvular dysfunction.  
Although studies have looked at LV mass in outcomes of AS(74, 79-82), this is less 
well studied in valvular regurgitation. Enriquez-Sarano did not demonstrate an  
association between LV mass and outcomes in mitral regurgitation, but did show an 
increase in LV mass with increasing size of the regurgitant orifice(208). Similar 
findings were observed in AR patients by Detaint et al(208), with increasing mass 
associated with increasing severity of AR in the absence of any independent effect on 
outcomes. 
3.12.7 Costs of screening for VHD in OxVALVE 
The cost of screening for VHD in this study was approximately £79.00 per 
participant recruited.  This cost includes room hire, administrative and staff costs, as 
well as consumables, but excludes the cost of the echocardiography machine. This 
equates to a cost of approximately £155.50 per patient newly diagnosed with VHD. 
When considering just those with moderate or severe VHD detected at screening, the 
cost rises significantly to £1234.40. However, the costs of leaving significant VHD 
undetected may be higher still. Looking at the costs associated with hospitalisation 
due to aortic valve disease alone in the first decade of this century, Badheka et al 
demonstrated a significant increase(242). The cost of a hospitalisation due to aortic 
valve disease in a patient over the age of 60 yrs increased from $31,909 to $38,172 
between 2000 and 2012. Extrapolating from these figures, the authors predict that the 
total cost of hospitalisation due to aortic valve disease in the United States will reach 
nearly $3 billion by 2020. Within the UK, Berry et al demonstrated a trend towards 
increasing hospitalisations due to aortic valve disease between 1997 and 2005(16). 
This suggests that a similar impact could be seen on the UK healthcare budget, with 
significant ramifications for resource management. Screening for VHD may allow 
more timely detection of significant lesions, thus permitting surveillance with prompt 
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intervention if required. Avoiding costly acute admission, in particular for heart 
failure, may justify the expenditure on screening. 
3.13 Conclusions 
Echocardiographic screening for VHD in a community-based setting demonstrates a 
high prevalence of previously undiagnosed VHD, although most is mild. The 
prevalence of VHD increases significantly with age, as does the likelihood of 
moderate or severe VHD. Mitral and aortic regurgitation are the most commonly 
detected forms of VHD. 
Female gender, atrial fibrillation, and lower body mass index are positively 
associated with a finding of mitral regurgitation. Current smoking status is associated 
with a increased likelihood of aortic stenosis. 
The finding of a significant prevalence of VHD in this expanding part of the 
population should add impetus to the search for better interventions (medical, 
surgical, percutaneous), improved methods of prognostication (imaging, genetic, 
biomarkers), and optimal detection and surveillance strategies. Investment in this 
may offset the morbidity and mortality currently seen with untreated severe valvular 
heart disease, and prove to be cost-saving in the longer term. 
3.14 Limitations 
This study had a response rate of 52% amongst those invited to participate. Although 
this is a high response rate in this setting, and within the constraints set by the Ethics 
Committee, there is the potential for those patients who are highly motivated and 
healthy, with fewer co-morbidities, to be represented; this would perhaps lead to an 
under-estimate of the prevalence of VHD by the study. 
The proportion of participants in each age band is higher in the younger age groups 
compared with the wider Oxfordshire population, and also the population of England 
and Wales. This reflects the level of frailty and co-morbidity amongst older invitees 
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who declined to participate. As the prevalence of VHD increases with age, and a 
previous diagnosis of VHD was an exclusion criterion, a higher proportion of 
potential invitees in the higher age bands will have been excluded on this basis. 
Despite these factors, the results demonstrate a significant increase in the prevalence 
of VHD with age, and if anything is likely to underestimate the prevalence of 
undiagnosed VHD in the age group studied. 
A lack of ethnic diversity may also affect the results of this study. The overwhelming 
majority (98.8%) of participants in this study classed themselves as white.  Although 
this is a good representation of the Oxfordshire population in the same age range 
(98% white), the broader UK population is more ethnically diverse than this. Table 
3.13 shows the breakdown of ethnic groups in the OxVALVE participants, the 
Oxfordshire population, and the population of England and Wales in UK residents 
aged 65 years and older(17). Compared with the wider Oxfordshire population, the 
proportion of study participants from a non-White ethnic background was slightly 
lower across most groups, with the exception of participants from a mixed ethnic 
background. This difference is also reflected in the comparison of study participants 
to the population of England and Wales, again with the exception of mixed ethnic 
residents.  
In order to address the disparity in ethnic diversity between study participants and the 
wider population, the choice of study sites took in to account the population served 
by the site. Sites were chosen with the intention of providing the covering broadest 
cross-section of ethnic and socio-economic possible. In addition, approval was 
sought from the Ethics Committee to engage with advocates within minority groups. 
Unfortunately this request was not approved, and it was not permitted to approach 
specific sectors of the community to increase engagement with the study. Study sites 
for the ongoing data collection of the study have also been targeted at areas with 
more diverse ethnic populations, as well as a broader socio-economic composition of 
the population.  
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Table 3.13 Comparison of ethic origins of OxVALVE participants with Oxfordshire 






England and Wales 
White (British, Irish, other white 
background) 
98.8 97.8 95.5 
Asian/Asian British 0.6 1.1 2.6 
Mixed/multiple ethnic group 0.4 0.3 0.4 
Black/African/Caribbean/Black 
British 
0.1 0.6 1.3 
Other 0.1 0.1 0.3 
Results are expressed as percentages. N=2500 for OxVALVE participants. 
Data for Oxfordshire population, and population of England and Wales taken from Office of 
National Statistics National Census 2011 data. 
 
It is possible that the recruitment of participants from other ethnic groups may affect 
the levels of rheumatic valve disease seen, as rheumatic valve disease remains a  
significant health care problem in less developed countries(6, 7).  Epidemiological 
studies in the United States have had a broader ethnic range, and have reported 
comparable prevalences to those found in this study, when taking in to consideration 
differences in inclusion criteria. 
Aortic stenosis has been shown to be associated with vascular risk factors, including 
factors associated with vascular calcification. Reduced bone mineral density has been 
demonstrated to be associated with aortic valve calcification and aortic stenosis(65, 
243, 244). This has raised the possibility that treatment for osteoporosis, such as 
bisphosphonates and denosumab, may help to slow or reverse the progression of AS.  
There is some evidence to support this from smaller studies(245, 246), and there is a 
randomised trial in progress to look at this further(247). The most commonly 
prescribed anticoagulant therapy, warfarin, has also been linked with vascular 
calcification and also calcification of the aortic valve(248-250). Although some data 
on the use of anticoagulation and additional medication was collected in the 
OxVALVE study, these data are incomplete. Data on whether or not participants had 
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been diagnosed with osteoporosis were also not captured by the study. The 
availability of such data would have provided the potential to look further at these 
factors in participants with and without aortic stenosis. This may be a target for 
future areas of study within the OxVALVE cohort in future. However, the study was 
established with a view to looking at all forms of VHD, and not simply aortic valve 
disease, hence the lack of robust data in these areas. 
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Chapter 4: Provocation of 
anxiety, and attitudes to 
screening for valvular heart 
disease 
4.1 Introduction 
In order to increase detection and intervention rates for VHD, data defining the scope 
of the problem are needed, and screening programmes must be considered. In 1968, 
principles for the evaluation of screening programmes were published by Wilson and 
Jungner, for the World Health Organisation(251). In essence, these say that an ideal 
screening test should be a safe, minimally-invasive, and cost-effective procedure that 
has a high sensitivity and specificity, and is easily administered, preferably in a 
community setting. It should identify a clinically significant condition, that will 
cause significant morbidity and mortality if left untreated. The condition being 
screened for should also have a pre-symptomatic phase during which the disease can 
be detected, and should have an accepted form of treatment. In the case of our study, 
VHD is a clinically significant condition, which may result in morbidity and 
mortality if timely surgical intervention is not undertaken, and the cost to healthcare 
of managing this is significant. Transthoracic echocardiography is safe, non-invasive 
and cost-effective, and modern compact portable machines permit widespread 
community-based use.  In experienced hands, it has an excellent sensitivity & 
specificity for the detection of VHD. Community-based echocardiographic 
programmes for screening for VHD would therefore seem to fit with the Wilson and 
Jungner principles for screening. 
Alongside this however, should also be the consideration of the possible harm which 
might be experienced by those being screened, particularly those who are found to 
have a false negative result. There has been much debate over the potential 
psychological impact of screening(252, 253), with concerns being raised about the 
potential for significant anxiety to be caused by such programmes, and the 
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acceptability of echocardiography in this setting have not previously been assessed. 
An assessment of these was therefore included within the OxVALVE study. 
4.2 Study questionnaires 
4.2.1 Completion of questionnaires 
At the end of visit 1, participants were asked to complete a study questionnaire. This 
consisted of two sections: the first part was the short form of the Spielberger State-
Trait Anxiety Inventory (STAI) to assess levels of anxiety provoked by participation 
in the study, and the second part was formulated to assess participants attitudes to 
screening for VHD. A copy of the full questionnaire is found at Annex A. 
Completion of the questionnaires was mostly undertaken independently by 
participants, in the GP waiting area, in order to avoid possible bias in responses. 
However, when participants required assistance of study staff to complete the 
questionnaire, this was provided. 
4.2.2 Spielberger State-Trait Anxiety Inventory 
questionnaires 
The Spielberger State-Trait Anxiety Inventory is a well-validated and widely-used 
measure of anxiety in applied psychology research(254). The full STAI consists of 
40 individual questions, and therefore is time-consuming to complete. However, a 
short form has been developed and validated(219), and has been used in similar 
settings to the OxVALVE study, in order to determine levels of anxiety provoked by 
screening(255). The short form consists of just six questions, with four or more 
responses sufficient for a meaningful result.  
Data from the STAI responses were input with inversion of the values from questions 
1, 4 and 5, as per the developers’ guidelines. Scores were then prorated, with a score 
of 42 or more representing clinically significant anxiety. 
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4.2.3 Attitudes to screening 
The second section of the survey assessed participants’ attitudes to screening and to 
the study delivery itself. This served two purposes: firstly it permitted adjustments to 
the way in which invitations to participate and study information were formulated 
and distributed if responses indicated dissatisfaction with the original methods; and 
secondly, it gave an insight into whether participants considered screening for VHD 
in general, and using echocardiography specifically, to be important and acceptable. 
This second aspect is of particular importance in the consideration of widespread 
screening for VHD. 
This section of the questionnaire was developed in collaboration with staff in the 
Department of Primary Healthcare of Oxford University. It was based on 
questionnaires used in research into screening for colorectal cancer(256), and asked  
questions to determine:  
• whether participants were aware of the programme prior to receiving an invitation 
to participate;  
• whether they found receiving a postal invitation to be satisfactory;  
• whether they would have preferred to have been offered the opportunity to 
participate when visiting the practice for another reason;  
• how important they considered healthcare screening in general; how important they 
considered screening for VHD;  
• whether they felt that the invitation letter explained the programme satisfactorily;  
• whether they would have echocardiography for VHD screening again. 
With the exception of responses relating to prior awareness of the study, answers 
were given on a five-point scale, with 1 representing Definitely Not/Not Important 
and 5 representing Definitely Yes/Very Important.  
Appendix 1 is the full B2 questionnaire, which contains the short STAI section and 
attitudes to screening questions, as provided to participants of the study. 
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4.3 Results 
4.3.1 Study population 
Of the first 2500 participants enrolled in the OxVALVE study, 2186 appropriately 
completed and returned the short STAI section of the questionnaire, and  2361 
completed the questions on attitudes to screening. A minimum of four out of six 
responses was required for completion of the STAI. The characteristics of 
questionnaire respondents are presented in Table 4.1. 
Table 4.1 Characteristics of questionnaire respondents 
Short STAI questions (N=2186) 
Age, mean (SD) 72.4 (6.0) 
Gender N (%) 
Male 1060 (48.5) 
Female 1126 (51.5) 
New diagnosis of VHD   
Yes 929 (42.5) 
No 1257 (57.5) 
 
Attitudes to screening questions (N=2361) 
Age, mean (SD) 72.9 (5.90) 
Gender N (%) 
Male 1138 (48.2) 
Female 1223 (51.8) 
New diagnosis of VHD   
Yes 975 (41.3) 
No 1386 (58.7) 
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4.3.2 Statistical analysis 
Participants were stratified by age, gender, and presence or absence of VHD to 
explore the prevalence of clinically significant anxiety scores in the study population.    
As not all of the first 2,500 participants of the OxVALVE study completed the 
questionnaires, summary statistics are presented for each of the questionnaires. 
Clinically significant anxiety levels are indicated by a score greater than 42. The chi-
square test or the Fisher’s exact test were used to compare discrete data as 
appropriate;  and non-parametric testing was carried out using the Mann-Whitney 
and Kruskal Wallis tests. The factors associated with a clinically significant anxiety 
score were assessed, and the chi-square test was also used to look at the association 
of a new diagnosis of VHD with a clinically significant score on the STAI 
questionnaire. 
4.3.3 STAI questionnaire 
Of the first 2500 participants recruited to the study, 2186 (87.4%) appropriately 
completed the STAI questionnaires. Out of these 2186, 5 participants (0.23%) 
answered 4 STAI questions, 26 participants (1.19%) answered 5 STAI questions, and 
2155 participants (98.58%) completed all six of the STAI questions. 223 respondents 
(10.2%) had a score >42, indicating a significant level of anxiety. Those with a 
significant anxiety score were more likely to be female than male (13.04% and 
9.05% respectively, p<0.001). Participants who received a new diagnosis of VHD 
were also more likely to have a STAI score >42, compared with those who were not 
found to have VHD (12.7% compared with 8.4%, p<0.001).  There was no 
association between age and anxiety score. These results are shown in table 4.2 and 
4.3. 
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Table 4.2 Association of gender, and new diagnosis of VHD with STAI score 
STAI score Male Female P value VHD - VHD + P value 
≤42 975 (92.0) 987 (87.7)  1151 (91.6) 811 (87.3)  
>42 85   (8.0) 138 (12.3) 0.001 105   (8.4) 118 (12.7) 0.001 
All values are expressed as numbers (%); p-value <0.05 was considered significant 
 
Table 4.3 Association of STAI score and age 
STAI score 65-69 70-74 75-79 80-84 ≥85 P value 
≤42 785 (90.0) 544 (89.6) 352 (87.6) 202 (94.0) 80 (88.9)  
>42 87 (10.0) 63  (10.4 50  (12.4) 13  (6.0) 10  (11.1) 0.78 
All values are expressed as numbers (%); p-value <0.05 was considered significant 
 
4.3.4 Attitudes to screening questions 
The first 2500 enrolled participants of the study yielded 2361 (94.4%) appropriately 
completed questionnaires on attitudes to screening. Only 21.5% of responders had 
heard of the study before they received their invitation to participate. 95.4% were 
satisfied with having received a postal invitation to participate, while 6.2% would 
have preferred to receive their invitation when visiting the surgery for another 
reason. The initial invitation letter was felt to explain the tests clearly by 96.5%, 
while only 0.5% felt that it did not explain the tests clearly. 
Health screening in general was felt to be important or very important by 97.2%, but 
was classed as not important or slightly important by 1.4%. On logistic regression, 
there was no association between age, gender or a new diagnosis of VHD and a 
positive attitude to the importance of health screening in general.  
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When asked specifically about screening for VHD, it was rated as important or very 
important by 95.9%, while 1.3% considered it to be slightly/not important, as 
demonstrated in Figure 4.1.  There was no significant difference in gender, age, or a 
new diagnosis of VHD amongst those who had a positive attitude towards screening 
for VHD, when compared with those who did not express a positive attitude.  
When asked whether they would be prepared to have the same test again, 98.5% 
responded yes or definitely yes; only 0.3% indicated that they would not undergo the 
screening test again, and 0.9% were unsure. There was no association between 
gender or a new diagnosis of VHD, and a willingness to undergo echocardiography 
again on logistic regression. However, age was strongly associated with whether or 
not a participant would be willing to undergo echocardiography again. Those who 
were older were less likely to express a willingness to undergo echocardiography in 
the future (OR 0.93; 95% CI 0.88,0.98; p=0.008). 
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4.4 Discussion 
These results demonstrate that in a community-based echocardiographic screening 
programme for VHD: 
1) A clinically significant level of anxiety are provoked only in a small number of 
participants, and is related to gender and diagnosis of VHD. 
2) Attitudes towards such a screening programme are positive, and the test is highly 
acceptable to patients. 
90
100






Age bands (years) Important/Very important
Unsure
Not/slightly important
Figure 4.1. Attitudes to the importance of screening for VHD by age band 
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4.4.1 Levels of anxiety provoked in screening for VHD in the 
community. 
Only a minority of participants (10.2%) indicated that the screening programme 
provoked clinically significant levels of anxiety, based on a score in excess of 42 on 
the short form of the Spielberger State-Trait Anxiety Inventory. This compares 
favourably with other studies looking at anxiety associated with screening 
programmes(39, 255, 257). The immediate availability of the results of screening 
may well play a role in this, as it has been shown that being given a result at the time 
of screening is more reassuring than having to wait(258). It might be expected that 
those with health-related anxiety might be more likely to  accept an invitation for 
screening, in which case high levels of self-reported anxiety might be expected. The 
low levels of anxiety expressed by participants in our study, however, would seem to 
suggest that this may not be the case. 
The association of increased anxiety levels with gender has not been previously 
explored in connection with screening programmes, and does not have any obvious 
explanation. Female participants may feel more comfortable admitting to personal 
levels of anxiety than male participants,  or the physical exposure associated with 
undergoing echocardiography may be more anxiety-provoking for women in this age 
group than their male counterparts. 
Although intuitively the finding that a new diagnosis of VHD on screening is 
significantly associated with higher levels of anxiety seems unsurprising, the findings 
of Lucarotti et al in abdominal aortic aneurysm screening do not support this(259). 
However, it does agree with findings of other screening  studies, which have 
demonstrated that being given a negative result from screening provides greatest 
reassurance(260-262). Although higher than those in the screen-negative group,  
anxiety levels were still low in the screen positive group (12.7%), which suggests 
that delivering results at the point of screening, and assurances by the study team that 
follow up arrangements would be put in place, may well have helped to alleviate 
participants’ concerns.  
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The timing of completion of the STAI questionnaire may be a factor in the finding of 
higher levels of anxiety in those with a new diagnosis of VHD. Participants who 
were informed that they had no VHD shortly before completing the STAI might have 
reflected this recent reassurance by reporting lower levels of anxiety than they would 
have reported prior to echocardiography. The opposite might be true for those 
receiving a new diagnosis of VHD. Screen positive participants were provided with a 
printed study leaflet, which explained what the results might mean for the 
participant, and outlined the likely future course of follow up, both within the study 
and potentially in out-patient clinics. However, at the time when participants were 
completing the STAI questionnaire at the study visit, they would not have had the 
opportunity to read the leaflet, and experienced any reassurance from receiving this 
information. 
4.4.2 Attitudes and acceptability in a VHD screening 
programme 
The relatively low levels of awareness of the screening programme amongst those 
being screened is not surprising in the context of a relatively small programme, 
operating relatively locally. Methods of publicising the study included placing 
posters in participating GP surgeries, and advertising the study on display screens in 
the surgeries; leaflets were also left on tables in the waiting rooms of participating 
practices. Despite the relatively small percentage of participants who were aware of 
the study prior to receiving their invitations, our uptake rate for the study was still 
good. 
The majority of participants expressed positive attitudes towards screening in 
general, and a very high percentage (94.2%) also expressed positive attitudes towards 
screening for VHD specifically. Marjoram et al found similarly positive levels in a 
small group of patients being offered screening for bowel cancer(256), and even in 
patients who have been found to have false positive results, Mant et al reported 
reported positive attitudes to screening(263).  
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Acceptability of echocardiography in the community to screen for VHD was also 
very high. When asked whether they would be willing to have the screening test 
again, 98.7% of participants answered either “Yes” or “Definitely yes”, as opposed 
to only 0.3% who replied “No” or “Definitely No”. This is significantly higher than 
that suggested by a study into compliance rates of those offered faecal occult blood 
testing for bowel cancer, reported by Hobbs et al(264), and is comparable to the high 
levels of acceptability reported by other screening studies(255, 263, 265). This is 
likely to be related to the non-invasive and non-painful nature of echocardiography, 
although it does require patients to expose their torso, which might be expected to be 
less acceptable for female patients.  
4.5 Limitations 
The main limitation of assessing anxiety and acceptability in this cohort, is that 
participants self-selected by either accepting or declining the invitation to participate. 
How this will potentially bias the findings is not clear as those who accept the 
screening invitation may have more baseline health concerns than those who don’t 
accept the invitation, and may have higher anxiety scores as a result; conversely, 
those with the highest levels of anxiety about screening may decline the invitation 
because of this, resulting in lower overall anxiety scores. Although obtaining data on 
anxiety from non-respondents is likely to prove challenging, and in our study would 
not have been permitted by the ethics committee, an assessment of pre-test anxiety 
levels may give an indication as to whether the screening experience itself influences 
anxiety levels for individuals. These data have been obtained for those who chose to 
participate in our study, and analysis of these data may be informative in this area. 
The STAI responses are also based on anxiety levels at a single point in time, and 
other studies have demonstrated changes in anxiety levels - both increasing and 
decreasing - in screening participants, when anxiety was assessed at least a month 
after the initial anxiety assessment(39, 259). Understanding whether screen-positive 
subjects have persistently raised levels of anxiety may allow interventions to 
alleviate this, and should stimulate further study of which particular factors cause 
psychological distress to this patient group. 
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The questionnaire was completed during the study visit, shortly after the participant 
had undergone echocardiography, and had been given the results of 
echocardiography. The timing of completion may have influenced the participants’ 
responses, and may be a factor in the finding of higher levels of anxiety in those with 
a new diagnosis of VHD. Although participants were provided with a leaflet 
explaining the diagnosis to them, they would not have had the opportunity to read 
this prior to completing the questionnaire, and anxiety levels may have been higher 
in these participants after their echo study had been performed than prior to it. 
Conversely, those who were informed that they had no VHD may been reported 
lower levels of anxiety by completing the questionnaire after receiving their results 
than if it had been completed prior to the echo. As the STAI questionnaire was 
incorporated into the same document as the questions on attitudes to screening, it 
was completed after echocardiography had been performed. This allowed 
participants to reflect their experience of echocardiography as a screening tool, and 
how acceptable they had found it. The two sections of the questionnaire could be 
completed at separate timepoints within the study visit, although this would affect the 
length and flow of the visit. 
A second STAI questionnaire was sent out to participants three months after their 
study visit, to assess how anxiety levels changed over time. Although these data have 
been collected, they are not currently available. 
A further limitation of this study is that data were not collected on specific mental 
health diagnoses. It may be the case that those who reported higher levels of anxiety 
had a pre-existing diagnosis of mental illness, which could have been the reason they 
felt anxious rather than because they were participating in the study. However, in 
those participants with a diagnosis of mental illness, particularly those with anxiety-
related disorders, medication used to treat the condition might have meant that they 
reported lower levels of anxiety. Mental illness may also have been undiagnosed in a 
proportion of participants, and this would possibly have affected their responses to 
the STAI, and they would not have been benefiting from receiving treatment for 
mental illness.  
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The use of antidepressants in participants may have provided an indicator of those 
more at risk of anxiety. Although participants were asked for complete data on their 
medication history, these data were not complete. Some medications which might be 
used as antidepressants or anxiolytics may also be used for other purposes, such as 
the use of amitriptyline for neuropathic pain or benzodiazepines for sleep disorders; 
some anxiety-related disorders might be treated with medication other than 
antidepressants, such as propranolol. Therefore the data available were not 
sufficiently robust as to be analysable in this context. A history of antidepressant or 
anxiolytic drug use could also have confounded results on anxiety. Participants who 
were taking such medications might have actually experienced comparable levels of 
anxiety to those not taking them as a result of the treatment. The variety of 
medications used to treat anxiety and depression is very broad, and the potential for 
confounding considerable and therefore these data cannot be considered to be robust 
in this context. 
4.6 Conclusions 
In a large cohort of elderly subjects, community-based echocardiographic screening 
for VHD does not provoke significant levels of anxiety, although clinically 
significant anxiety scores are more common among women and those found to be 
screen-positive. Attitudes towards health screening in general, and screening for 
VHD in particular, are positive. Echocardiography as a screening test for VHD is 
highly acceptable to patients. 
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Chapter 5: Cardiac magnetic 
resonance for predicting 
outcomes in mitral regurgitation 
5.1 Introduction 
The optimal timing of surgery in mitral regurgitation remains a source of discussion, 
with the risks of early surgery, and possibility of valve replacement rather than 
repair, being weighed against the possibility of irreversible myocardial damage if 
severe regurgitation remains untreated for too long. Quantitation of mitral 
regurgitation using echocardiography has been shown to relate to outcomes(12, 171), 
but semi-quantitative methods are more commonly used in routine clinical practice. 
CMR can quantify mitral regurgitant volume and fraction, using phase-contrast 
velocity mapping and measurement of left ventricular volumes and systolic function. 
Trans-aortic flow measured in this way has been shown to correlate with in vivo and 
in vitro stroke volume measurements(266-269), and CMR is regarded as the ‘gold 
standard’ for measurement of LV volumes. The indirect calculation of mitral 
regurgitant volume by subtraction of aortic flow from LV stroke volume optimises 
inter- and intra-observer variability(202), and also allows the potential to correct for 
co-existent aortic regurgitation. Trans-thoracic echocardiography is the most widely 
used tool for the longitudinal assessment of valvular heart disease, including mitral 
regurgitation. Its relatively low cost, lack of ionising radiation, and non-invasive 
nature make it an ideal tool for this. However, quantitative parameters for the grading 
of MR severity rely on optimal image quality, in the presence of central jets through 
non-elliptical regurgitant orifices in order to optimise accuracy; this combination of 
qualities is not always present in the real-world patient population. 
In this chapter, the utility of quantitative CMR assessment of MR to predict 
outcomes is considered. A comparison study of MR quantitation using the PISA 
method and two-dimensional trans-thoracic echocardiography is also presented. 
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5.2 General methods 
5.2.1 Subject recruitment, inclusion and exclusion criteria 
Asymptomatic patients with primary mitral regurgitation of greater than mild 
severity (according to established echocardiographic criteria(22)), with no other 
indications for mitral surgery, were identified from 4 high-volume CMR centres, 
three in the United Kingdom (Oxford, Leeds, and Royal Brompton Hospital, 
London) and one in New Zealand (Aukland). In Oxford, patients participated in a 
research study, as described below, with annual CMR scans; decisions on clinical 
management were made without knowledge of the results of CMR scans. In the other 
three centres, study patients were identified from the clinical databases of CMR 
studies, and CMR scan results were available to clinicians. Asymptomatic patients, 
with no other indications for mitral valve surgery, were recruited in order to allow 
longitudinal follow up, and to avoid the potential bias of patients undergoing a CMR 
scan with surgery already planned. This patient group is of particular interest, as 
predictors of progression to surgical intervention, and the optimum time for that 
intervention to take place, remain unclear. Patients were followed for up to 8.2 years; 
those who remained asymptomatic and were managed conservatively are described 
as the conservative group, and those who became symptomatic or reached thresholds 
for surgical intervention are described as the crossover group. In the crossover group, 
the point of censoring is the point at which decisions about surgery were made. All 
decisions on clinical management were made by the treating physician. 
Subjects were eligible for inclusion in the study if they fulfilled the following 
criteria:  
• Aged 18 or above 
• Had provided informed consent 
• Had asymptomatic mitral regurgitation of greater than mild severity on 
echocardiography 
Subjects were excluded from participating if any of the following applied: 
• Any other significant (>mild) valvular heart disease 
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• Any contraindications to CMR scanning (pacemakers, implantable defibrillators, 
other metallic implants) 
• Evidence of significant coronary artery disease 
As the sizes of the two groups (conservative and crossover) and the survival 
outcomes were also unknown, a power calculation was not undertaken before 
recruitment commenced. A post-hoc power calculation using the actual survival and 
group sizes using the cut-off for regurgitant volume was therefore undertaken. Using  
surgery- or symptom-free survival of 91% and 21% for a regurgitant fraction of 
≤55ml/beat and >55ml/beat respectively, with 85% power (β error) and 95% 
confidence (α error), the total sample size required is 49. The total sample size for 
the study presented here was 109 participants. 
Those participants recruited in Oxford who were included in the sub-study described 
in section 3 of this chapter, were prospectively recruited from November 2009 to 
April 2011 from outpatient clinics at the John Radcliffe Hospital and surrounding 
hospitals in Oxford. Each participant gave written, informed consent to participate in 
the study, which was approved by the Central Oxfordshire Research Ethics 
Committee (C02.020). 
5.2.2 CMR scanning 
All patients were scanned on 1.5T scanners (Siemens Avanto [Siemens Medical 
Solutions, Erlangen, Germany] or Philips Achieva scanners [Philips Healthcare, 
Best, The Netherlands]. Subjects underwent ECG-gated scanning, which measured: 
• right and left ventricular volumes and function 
• left ventricular mass 
• aortic valve flow. 
Scans were analysed in each centre using the manufacturer’s software (Siemens 
Argus and Philips ViewForum respectively), to measure volumes and flow.  
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5.3 CMR and 2D TTE sub-study methods 
5.3.1 Subject recruitment, inclusion and exclusion criteria 
Subject recruitment, and study inclusion and exclusion criteria are as described in 
section 2.1 of this chapter. 
5.3.2 Clinical assessment 
On the day of scanning, all participants completed a clinical assessment. A focussed 
medical history was obtained, and the following were documented: 
• The presence or absence of any exclusion criteria 
• The presence or absence of cardiovascular symptoms, with particular attention to 
shortness of breath, palpitations, and ankle swelling 
• Assessment of New York Heart Association class 
• Current medications 
The following physical measurements were also recorded: 
• Height (cm) 
• Weight (kg), using calibrated scales 
• Blood pressure (using an automatic sphygmomanometer, Omron M6 blood 
pressure monitor, Kyoto, Japan) 
• Pulse rate and rhythm 
Participants then underwent transthoracic echocardiography and a cardiac magnetic 
resonance scan on the same day. 
5.3.3 Echocardiography scan protocol 
Trans-thoracic echocardiography was performed using a Philips iE33 advanced echo 
system (Philips Medical Systems, Best, Netherlands), equipped with 2-5-3.5Mhz 
transducers. 
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A full echo study was performed according to the European and American Society 
for Echocardiography guidelines for the assessment of native valvular 
regurgitation(33), and chamber quantification(270). Left ventricular volumes and 
ejection fraction were calculated according to Simpson’s rule.  
Assessment of the regurgitant flow was calculated from the proximal isovelocity 
surface area (PISA). PISA was measured by obtaining optimal images of the mitral 
valve in the apical 4-chamber view with colour flow mapping displaying the 
regurgitant jet at the Nyqvist limit at 40cm/s. Radius of the PISA was used to 
calculate regurgitant flow, according to the formula: 
Regurgitant flow = 2Πr2 x aliasing velocity 
where r is the PISA radius. 
 
5.3.4 CMR imaging scan protocol 
All scanning was performed on a Siemens 1.5T Avanto MR system (Erlangen, 
Germany), with scans lasting approximately 30-35 minutes. Subjects underwent a 
CMR scan protocol which measured the following: 
• Cardiac function and left ventricular mass 
• Aortic valve flow, using standard through-plane breath-hold sequences  
5.4 Cardiac mass, volumes and function 
CMR Steady-State Free Precession (SSFP) sequences are well established as an 
accurate, reproducible and valid method for the measurement of left ventricular 
volumes and mass(192-195). Pilot images, horizontal and vertical long axis images, 
and a short axis stack were acquired for the calculation of cardiac volumes and 
function, with participants in the supine position, as per standard CMR 
protocols(271). Slices were 7mm thick, with a 3mm gap, and images were acquired 
during a breath-hold at end-expiration to minimise the effects of respiratory motion 
on image quality. Images were retrospectively gated for patients in sinus rhythm, and 
prospectively triggered for patients in atrial fibrillation. 
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Epicardial and endocardial borders were manually contoured using the 
manufacturers’ software, in order to calculate end diastolic volumes (EDV), end 
systolic volumes (ESV), stroke volumes (SV), ejection fraction (EF) and myocardial 
mass. 
 
5.5 Aortic flow assessment 
Aortic flow (Ao flow) was measured using through-plane phase-contrast velocity 
mapping, which is accepted as a reproducible CMR technique for quantification of 
flow. Left ventricular outflow tract (LVOT) and coronal LVOT images were 
obtained, and  an  image slice for the flow sequence was placed perpendicular to the 
direction of flow in the aortic root, just above the valve at end diastole. The majority 
of patients were imaged using breath-hold sequences were used to acquire data 
within a single breath-hold (12-16 heartbeats); one centre routinely used non-breath-
hold sequences. All sequences were acquired with the region of interest at the 
isocenter of the magnet, in order to minimise any inhomogeneities in the magnetic 
field, which might give rise to background flow offset errors. 
From the resulting flow images, using the manufacturers’ software, a region of 
interest in the aortic root was defined and flow was measured by integrating the flow 
Figure 5.1 Measurement of LV volumes and ejection fraction.  
LV contoured in diastole (A) and in systole (B). 
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in each frame over a single cardiac cycle, as previously described(272). Regurgitant 
volume (RVol) was calculated as LVSV - Ao flow (ml); regurgitant fraction (RFrac) 
was calculated as (RVol/LVSV) x 100 (%). 
 
5.6 Clinical follow up 
Follow up information came from examination of hospital records. Those who 
developed symptoms, or reached other indications for surgical intervention, were 
censored at the point at which surgical intervention was considered. Participants who 
did not meet these criteria were censored at last clinic visit occurring during the 
study period. The clinical management of participants was independently decided by 
the treating clinicians. Events were only counted if the reason for mitral valve 
surgery was for established indications(22), which do not include CMR assessment. 
Figure 5.2 Position of imaging plane for CMR 
measurement of aortic valve flow 
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5.7 Statistical analysis 
T-tests were used to compare parameters between the two groups. Receiver operating 
characteristic curve (ROC) analysis was used to determine the ability of parameters 
to discriminate between those patients who would develop symptoms or other 
recognised indications for surgery, and those who would not. Differences in ROC 
area were compared using the method of DeLong et al(273). Kaplan-Meier curves 
were generated to demonstrate associations with progression to symptoms or 
indications for surgery. All analyses were performed with SPSS version 20 (SPSS 
Inc, IL), except for the ROC analyses, which were performed on MedCalc version 
14.12.0 (MedCalc Software, Mariakerke, Belgium). Results are expressed as 
mean±standard deviation, and a p-value of <0.05 was considered significant. 
5.8 Main study results 
5.8.1 Study population characteristics 
One hundred and nine patients with asymptomatic MR of more than mild severity, 
were included in the study. They were followed up for up to 8.2 years (mean 2.3 yrs). 
Participant demographics are presented in Table 5.1. The mean age of participants 
was 65 years (range: 24-86), and 35 patients were female. There was no significant 
difference in characteristics of patients in the two groups at baseline. 
Table 5.1 Patient Demographics 
Patient characteristics Conservative Group  
(N=84) 
Crossover Group  
(N=25) 
P value 
Age, mean (range) 65.18 (24-86) 63.75 (30-86) 0.664 
Male, n (%) 74 (80.66) 19 (76.00) 0.327 
BSA, m2  1.88±0.18 1.89±0.24 0.821 
Symptom status    
NYHA I, n (%) 68 (80.95) 17 (68.00)  
NYHA II, n (%) 5 (5.95) 5 (20.00)  
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Table 5.1 Patient Demographics 
NYHA III, n (%) 2 (2.38) 1 (4.00)  
NYHA IV, n (%) 0 (0.00) 0 (0.00) 0.115 
Haemodynamics    
Heart rate, bpm 68±13 67±10 0.778 
Atrial fibrillation, n (%) 16 (19.05) 8 (32.00) 0.173 
Systolic BP, mmHg 144±23 132±20 0.87 
Diastolic BP, mmHg 78±11 77±9 0.908 
Values expressed as mean±SD, unless otherwise indicated; p value <0.05 was considered 
significant;  BSA: body surface area; NYHA: New York Heart Association class; BP: blood 
pressure 
 
5.8.2 Cardiac magnetic resonance 
Volumetric and flow data were available for all patients. Results are displayed  in 
Table 5.2. Volumetric indices (LVEDV and LVESV), and their indexed values, were 
significantly higher in those in the crossover group. Ejection fraction was not 
significantly different between the two groups (p=0.84), suggesting that these 
patients had not developed significant LV systolic dysfunction as a result of their 
mitral valve disease. As might be expected, quantitative CMR measures of mitral 
regurgitation (regurgitant volume and fraction) were significantly lower in those in 
the conservative group, compared with those progressing to surgery (p=<0.001 for 
both parameters). 
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Table 5.2 CMR data 
CMR data (N=109) Conservative Group  
(N=84) 
Crossover Group  
(N=25) 
p-value 
LVEDV, ml 183±50 224±48 <0.001 
LVEDV index, ml/m2 98±25 118±23 0.001 
LVESV, ml 62±26 82±29 0.002 
LVESV index, ml/m2 34±14 43±13 0.005 
LVEF, % 67±8 64±7 0.84 
Regurgitant volume, ml 39±20 66±24 <0.001 
Regurgitant fraction, % 32±12 46±12 <0.001 
Values are expressed as mean±SD, in the units indicated. LVEDV: left ventricular end 
diastolic volume; LVESV: left ventricular end systolic volume; LVEF: left ventricular 
ejection fraction 
 
5.8.3 Predictors of progression to symptoms or surgery 
During the follow up period, 25 (22.9%) patients underwent mitral valve surgery for 
symptoms (n=9) or established indications for surgery (reduced LV systolic function 
[<60%] on echo, LV dilatation [LVESD>45mm], onset of atrial fibrillation, 
pulmonary hypertension [pulmonary artery systolic pressure >50mmHg with no 
other cause]).  Mean time from CMR scan to surgery was 23 months, median was 1.1 
years.  
Receiver-operator characteristic (ROC) analysis showed that quantitative measures 
of MR on baseline CMR scans had good discriminatory power. The AUC for mitral 
regurgitant volume was 0.81 (P<0.0001; 95% CI: 0.721;0.877). Using a cut-off value 
of >55ml/beat, it has a good sensitivity (72%) and high specificity (87%) for 
identifying those who progressed to symptoms or surgery. Regurgitant fraction for 
MR was only slightly less discriminating, with an AUC of 0.79 (P<0.0001; 95%CI: 
0.699;0.860). A cut-off value of 40% has a sensitivity of 76%, and specificity of 
74%, for identifying those progressing to surgical indications. The use of higher 
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thresholds for regurgitant fraction can allow prediction of progression with an even 
greater degree of certainty; when a cut-off value of 50% RFrac is used, the 
specificity increases to 92%, although with a lower sensitivity (40%).  
In order to examine the effect of time on progression to symptoms/surgery, Kaplan-
Meier survival curves were generated, using the discriminator values identified on 
ROC analysis. For both regurgitant volume and regurgitant fraction, there was 
significant separation of the groups with time (see Figures 5.3 & 5.4). For those 
patients with regurgitant volume ≤55ml/beat, survival without surgery at the median  
time point (1.1 years) was 95%. In those with a regurgitant fraction >55ml/beat, 
survival without surgery at the same time point was only 69%. Similarly, when using 
a cut off value of 40% for regurgitant fraction, survival without surgery is 94% for 
those with a regurgitant fraction ≤40%, compared to 79% for those with a regurgitant 
fraction >40%. 
Figure 5.3 Kaplan-Meier graphs for survival without surgery 
stratified by RVol ≤55ml/beat and >55ml/beat 
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5.9 CMR and 2D TTE comparison 
5.9.1 Study population 
Thirty-nine patients, who were recruited for the main study, also underwent 
transthoracic echocardiography, as described in section 3.3 above. Of these patients, 
2 were unable to complete the CMR scan, and 1 patient had inadequate echo 
windows to allow quantitative assessment of MR severity. Thirty-six patients had 
complete TTE and CMR data; the demographics of these patients are shown in table 
5.3. 
Figure 5.4 Kaplan-Meier graph for survival without surgery 
stratified by RFrac ≤40% and >40% 
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Table 5.3 Demographic data 
Patient characteristics (N=36) 
Age, mean (range) 66.9 (35-86) 
Male, n (%) 30 (83.3) 
BSA, m2   1.92±.19 
Symptom status 
NYHA Class I, n (%) 33 (91.7) 
NYHA Class II, n (%) 3 (8.3) 
NYHA Class III/IV, n (%) 0 (0.0) 
Haemodynamics 
Heart rate, bpm 70±12 
Atrial fibrillation, n (%) 10 (27.8) 
Systolic BP, mmHg 142±21 
Diastolic BP, mmHg 77±11 
Values are expressed as mean±SD, unless otherwise indicated; BSA: body surface area; 
NYHA: New York Heart Association; BP: blood pressure 
 
5.9.2 Echocardiographic and CMR data 
Echocardiographic and CMR measures of regurgitant volume were available for all 
thirty-six patients.  Results are displayed in table 5.4.  
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Table 5.4 CMR and echocardiographic data 
CMR data 
LVEDV, ml 190±51 
LVESV, ml 61±25 
Regurgitant Volume, ml 44±22 
Regurgitant Fraction, % 33±13 
MR severity by Rvol on CMR 
Mild, n (%) 12 (33.3) 
Moderate, n (%) 15 (41.7) 
Severe, n (%) 9 (25.0) 
 
Echo data 
MR Vmax, cm/s 486±81 
PISA radius, cm 1.03±0.54 
Regurgitant Volume, ml 83±86 
EROA, cm2 0.68±0.92 
MR severity by Rvol on 2DTTE 
Mild, n (%) 6 (16.7) 
Moderate, n (%) 15 (41.7) 
Severe, n (%) 15 (41.7) 
Values are expressed as mean±SD in the units stated; LVEDV: left ventricular end 
diastolic volume; LVESV: left ventricular end systolic volume; Rvol: Regurgitant volume; 
MR V max: maximum velocity of the MR jet on Continuous Wave Doppler; PISA: Proximal 
isovelocity surface area; EROA: Effective regurgitant orifice area. 
 
MR severity was classified by regurgitant volume as mild, moderate or severe, 
according to the established echocardiographic values(33). According to Rvol 
measured on CMR, 12 patients (33.3%) had mild MR, 15 patients (41.7%) had 
moderate MR, and 9 patients (25.0%) had severe MR. In comparison, based on Rvol 
by 2DTTE, 6 patients (16.7%) had mild MR, 15 patients (41.7%) had moderate MR, 
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and 15 patients (41.7%) had severe MR. 2DTTE overestimated the severity of  MR 
in 14 patients (38.9%), and underestimated the severity of MR in 2 patients (5.6%).  
Figure 5.5 shows the number of patients classified in the same versus different mitral 
regurgitation severity grade. 
 
Bland-Altman plots were used to demonstrate the agreement between CMR and 
2DTTE measures of RVol (figure 5.6). Two-dimensional transthoracic echo 
overestimated the regurgitant volume by an average of 36ml/beat (95% limits of 
agreement -92ml/beat; 164ml/beat). There were two outliers in the dataset, which 


















Figure 5.5 Number of patients classified in the same versus different grade of 
severity of mitral regurgitation, as measured by 2DTTE and CMR 
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regurgitant volume, compared with CMR, by 22ml (95% limits of agreement -
39ml/beat; 83ml/beat). 
5.10 Discussion 
5.10.1 CMR quantitation of MR is feasible. 
This study confirms that the use of CMR in the assessment of MR is feasible. In the 
four high-volume CMR centres participating in the main study, quantitative measures 
of mitral regurgitant volume and fraction could be obtained using CMR scanners in 
routine clinical use, utilising imaging sequences in standard clinical practice. CMR 
imaging has been well validated for ventricular volumes and for trans-aortic flow by 
phase-contrast velocity mapping(192-195, 266-269). CMR has now been used in a 
range of studies of valvular heart disease, including those of patients with MR. The 
techniques are now established and validated, as described clearly by Cawley et 
al(272). These studies include only small numbers of participants, and so the study 
Figure 5.6 Bland-Altman plot demonstrating the agreement in 
measurements of regurgitant volume between 2DTTE and CMR. 
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presented here confirms the feasibility of using CMR in a broader, more real-world 
population. In the sub-study, the CMR scan was well-tolerated, with 95% of 
participants completing the scan protocol, although data on tolerability of CMR from 
other centres was not available. 
5.10.2 Quantitative CMR measures of MR for predicting 
outcome 
These data suggest that the quantitative assessment of MR by CMR has the potential 
to risk stratify patients with primary mitral regurgitation, and allow identification of 
those at highest and lowest risk of progressing to symptoms or surgery. This is in 
keeping with previous work in patients with aortic regurgitation(203). This is 
important as the management of patients with severe MR is contentious and 
challenging, and markers of risk are poorly defined.  
Enriquez-Sarano et al demonstrated that echocardiographic quantitation of MR can 
be of value in predicting outcomes(12), but echo quantification can be inhibited by 
poor acoustic windows, geometric assumptions, and eccentric regurgitant jets(274, 
275). These factors are less of a challenge in CMR, which has been shown to 
correlate well with echo and angiographic assessment, with good 
reproducibility(202, 276, 277). Despite this, there are no published studies of the 
prognostic significance of CMR quantitation of MR.  
The identification of those with regurgitant volumes or fractions above the threshold 
values described above may select individuals most likely to benefit from the closest 
follow up. It may also assist in targeting suitable candidates for early surgery for 
MR.  At the other end of the spectrum, those with the lowest regurgitant volumes - 
the “milder moderate” patients - may be suitable for longer intervals between follow 
up, which would be both time- and cost-saving. These considerations would need 
evidence from further studies if they were to be incorporated into standard clinical 
practice, especially with respect to surgical indications. 
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The threshold values suggested by the data presented here are similar to those 
recommended as cut-off values for the echocardiographic assessment of MR(33). 
These suggest that RVol ≥60ml/beat represents severe MR, which is comparable to 
the >55ml/beat suggested on ROC analysis of these CMR data. Regurgitant fraction 
by echocardiography has a slightly higher cut-off value for echo, compared with the 
proposed value according to the CMR data (≥50% vs >40%, respectively). In those 
graded as moderate MR on echo criteria, 45% of patients went on to require surgery 
in the Enriquez-Sarano study, and therefore using the CMR values suggested may be 
more discriminatory.  
5.10.3 Comparison of 2DTTE and CMR for assessment of MR 
The PISA method for echo quantification of mitral regurgitation has been validated 
in experimental and in clinical settings(181-183), but it relies on certain assumptions. 
Although in a single-centre study reproducibility has been shown to be good(172), 
inter-observer variability is significant between centres(174). The calculation of 
PISA = 2Πr2 assumes a hemispheric isovelocity surface area, and with a non-
elliptical regurgitant orifice. If the MR jet interacts with one of the mitral valve 
leaflets or the wall of the left ventricle, then the PISA is non-hemispheric. Although 
this can be corrected for using a correcting factor(278), this is assessed by the 
operator, introducing a significant potential source of error. In eccentric jets, 
alignment with the Doppler beam is affected, and this leads to further inaccuracies in 
the calculation of RVol. Where more than one jet of MR is present, the calculation of 
RVol or EROA using PISA is also inaccurate. Although individual values could be 
calculated from each PISA and the results summed, this would be very time-
consuming. Overlapping PISA jets, or distortion of shells will also create 
inaccuracies in this setting. CMR measurement of flow and calculation of RVol in 
MR avoids these assumptions.  
The data from 36 patients in the study described above demonstrate a poor 
correlation between RVol on CMR scanning, and RVol calculated using 2DTTE and 
the PISA method. 2DTTE overestimated the RVol, when compared with CMR, by a 
mean of 38ml/beat. Both techniques have been validated using experimental and 
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clinical methods(33, 202, 272, 279). In a study by Cawley et al, CMR had lower 
inter- and intra-observer variability when compared to 2DTTE for the measurement 
of regurgitant volume in AR(196). In the same study, there was significant variability 
in measures of regurgitant volume for the assessment of MR for both imaging 
techniques. However, there is no gold-standard method against which CMR and 
2DTTE can be measured in order to determine which of these methods is the more 
accurate.  
There are few other studies which compare the two methods of assessing MR. 
Shanks et al compared CMR assessment of MR with quantitative measures on trans-
oesophageal echo, and demonstrated a consistent underestimation of RVol by 
echo(280), which is the opposite of the finding of this study.  Cawley et al assessed 
both aortic and mitral regurgitation assessment by TTE and CMR(196). Although the 
main aim of the study was to examine intra- and inter observer measurement 
variability, the authors also conducted a comparison of inter modality measures of 
regurgitant severity. This demonstrated a good correlation overall, but with 
significant scatter of the data. TTE again tended to underestimate the RVol compared 
with CMR, in contrast with the data reported here. It is not clear why the data from 
the comparison study reported here differ from both of these studies. Apart from the 
use of TOE in one study, the only obvious difference in the study populations in that 
atrial fibrillation was not an exclusion criterion for this study, whereas patients in the 
other two reported studies were in sinus rhythm. Although this might have made a 
modest difference, it is unlikely to fully account for the results obtained.  
5.11 Conclusions 
Quantitative CMR assessment of mitral regurgitation has the potential to be a useful 
tool for the risk stratification of this patient group, and can assist in predicting 
outcomes. In trying to identify patients suitable for early surgical intervention with 
mitral valve repair, these parameters may be useful, but larger clinical trials would be 
required to confirm this. 
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Phase-contrast velocity mapping by CMR to measure mitral regurgitant volume does 
not correlate well with RVol calculated by the PISA method on 2DTTE in a small, 
unselected population with clinically significant mitral regurgitation. 
5.12 Limitations 
Although data were gathered in four high-volume CMR centres, the sample size is 
modest, which limits the strength of the conclusions that can be drawn from these 
data, as a relatively small number of events occurred. However, the length of clinical 
follow-up was reasonable (mean 2.3 years, up to 8.6 years). 
Although in one centre clinicians were blinded to the results of the CMR scans when 
deciding on clinical management, scan results were available to the treating 
physician in the other three centres. This may have resulted in a degree of bias.  
Another potential source of bias is that those patients referred by their treating 
physician for CMR assessment of MR may have been managed more proactively. 
However there are currently no CMR criteria for recommending surgery in MR, and 
those patients who went on to have surgery within thirty days of their CMR scan 
were excluded from the analysis. Patients who underwent surgery for indications 
outside the established criteria for MR surgery were also excluded. When the 
progression to surgery of those patients who were prospectively enrolled in a 
research study was compared to those scanned for clinical purposes, there was no 
significant differences found between centres (p=0.80 by logrank test). 
CMR scanners, and analysis software, were not identical in all of the four different 
centres, although it would be expected that this would not result in significantly 
different measures of identical parameters. 
When only quantitative echocardiographic thresholds of severity (EROA of < or 
≥0.40cm2 are used to predict progression to symptoms or surgery, the separation of 
survival curves was modest, and the difference in outcome was not statistically 
significant (p=0.36). Outcomes were similar when regurgitant volume by echo was 
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assessed, using a threshold of >60ml. However, the numbers in this sub-group were 
small (n=53), limiting the studies ability to demonstrate an incremental benefit in 
prognostication for CMR when compared to echocardiography. When CMR 
quantification uses echocardiographic parameters for MR severity to look at 
outcomes, separation of the survival curves has been shown to be similar between 
moderate and severe MR compared with milder regurgitation(281). Larger studies 
are warranted to assess the utility of CMR and echocardiography in this context, and 
investigate whether the higher costs and time burden of CMR is justified by a greater 
ability to prognosticate over echo in these patients. 
The sample size for the comparison of 2DTTE and CMR measurements of RVol was 
small, although it is the same size as that used by Shanks et al, and larger than that 
reported by Cawley et al. Regurgitant jets in this unselected group were frequently 
eccentric, and therefore highly likely to be prone to error in the calculation of RVol 
using the PISA method. However, this is a real-world study and serves to highlight 
the very real limitations of a widely used method of assessing MR severity.  
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Chapter 6: Summary 
6.1 Summary 
6.1.1 Aims of the original work 
This work was undertaken with two broad main aims: 
• To describe the epidemiology of contemporary VHD in a developed country, 
through the use of a community-based echocardiographic screening programme, as 
well as evaluating the related anxiety and acceptability of such a programme; 
• To evaluate the use of CMR quantitation for the prognostication in patients with 
mitral regurgitation, and compare it with a commonly used echocardiographic 
measure of regurgitation. 
In this chapter, the extent to which these aims have been achieved, the utility of these 
findings in clinical practice, and areas for future research will be discussed. 
6.1.2 The epidemiology of valvular heart disease 
As discussed earlier in this work, the nature of valvular heart disease in the 
developed world has changed over the last century. There are few data available on 
the epidemiology of modern VHD(5, 8), and to date there are no prospective 
community-based studies of this. The work of OxVALVE PCS delineates the 
modern prevalence of VHD, and evaluates the relationship of VHD with established 
risk factors for cardiovascular disease. 
The data from OxVALVE PCS presented herein demonstrate that there is a high 
prevalence of undiagnosed VHD among those aged 65 years and above, and that the 
prevalence increase markedly with age. Although most undiagnosed VHD is mild in 
severity, a significant number of this section of the population have more severe 
VHD, which may need intervention at some stage. In order to benefit from an 
improved appreciation of the burden of undiagnosed VHD in our population, 
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clinicians must consider what steps are necessary to decrease the numbers of 
undiagnosed patients. Education of primary care providers may increase their index 
of suspicion of VHD in older patients who have some of the risk factors identified by 
OxVALVE PCS and other studies. An increased awareness of the general population 
about the importance of VHD and its outcomes may prove beneficial by prompting 
patients to ask to have their heart listened to when seen by their general practitioner. 
Engagement with charities and patient awareness groups will also bear fruit. Heart 
Valve Voice has started work in this area. The charity has run screening days at large 
sporting events, such as football and cricket matches, to raise awareness and increase 
detection rates. Whilst enthusiasm for improving detection rates and hopefully 
outcomes is laudable, careful planning is required to ensure appropriate mechanisms 
for providing reassurance and follow up to screen positive patients. Opportunistic 
auscultation may increase the detection rates in primary and secondary care, but will 
require adequate provision of echocardiographic services in order to assess those 
found to have a murmur. 
Hypertension and atrial fibrillation (AF) were identified as risk factors for 
undiagnosed valve disease in OxVALVE PCS. The current National Institute for 
Health and Care Excellence (NICE) guidelines recommend echocardiography in the 
assessment of many patients with AF(282), and suggest consideration of 
echocardiography in those with hypertension to look for evidence of end organ 
damage in certain patient groups(283). Adherence to these guidelines may lead to an 
increase in the detection rate of VHD.  
Increasing age was the strongest predictor of VHD, as might be expected. 
Understanding of the age patterns associated with VHD allows the targeting of 
potential screening programmes to optimise uptake and yield. A recent article 
produced by the British Heart Valve Society suggested screening those aged 75 years 
and older(43). According to the data from OxVALVE PCS presented here, this 
approach would mean that over one third (34.1%) of moderate or more valve disease 
in those aged 65 years or older would go undetected. Arguably these younger 
patients have the most to gain in terms of life expectancy if their VHD is detected in 
a timely manner. The finding that a proportion of those who declined the invitation to 
  MD Thesis: Joanna d’Arcy 
  132 
participate in OxVALVE PCS did so as they felt they were too old is challenging. 
Those in the highest age groups have the highest risk of significant VHD, but also 
have the highest level of comorbidity. Age was also the most frequently cited reason 
for medical management of VHD in the Euro Heart Survey(5). However, outcomes 
in the oldest age groups undergoing intervention are also improving with time(37). 
Patients and clinicians must be made aware of these good outcomes, the potential 
benefits to patients, the outcomes associated with lack of intervention, and the 
potential for newer minimally invasive techniques. 
As well as elucidating the contemporary prevalence of VHD, the data in chapter 4 
also demonstrate the acceptability of a community-based echocardiographic 
screening programme to the target population. A high level of acceptability is a pre-
requisite of a successful screening programme, in terms of yield and also cost-
effectiveness. Our study also confirms the feasibility of a community-based 
programme, when established with the engagement of primary care practitioners. An 
uptake rate of approximately fifty per cent is lower than other screening studies(205), 
but formal screening studies would not be subject to the same constraints imposed on 
OxVALVE PCS by the ethics committee. Increased awareness and promotion of a 
formal screening programme may lead to a greater proportion of the target 
population attending for screening. In order for such a programme to be successful, it 
would need to involve a clearly defined pathway for referral in those found to have 
VHD, and adequate resources to provide surveillance must also be available. A 
variety of possible methods for providing such a screening programme have been 
suggested(43), and the best approach will vary according to the setting. 
The potential for provoking high levels of anxiety with screening is an important 
consideration. The work presented here suggest that, in line with similar studies(166, 
167, 169, 255, 259), this is not a significant factor in VHD screening. This provides 
reassurance, to both clinicians and patients, that an increased detection rate of VHD 
is not accompanied by an unacceptable burden of anxiety and emotional distress. A 
proactive approach to minimising anxiety associated with undergoing screening can 
be attenuated by providing clear descriptions of what patients can expect when 
attending. Following a positive diagnosis of VHD, patients should be given prompt 
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reassurance that follow up will be arranged, and adequate and appropriate 
information on the implications of their diagnosis. 
6.1.3 Quantification and prognostication in mitral 
regurgitation 
In chapter 5, it was shown that CMR quantification of mitral regurgitation is 
associated with outcomes. Those with a regurgitant volume greater than 55ml/beat, 
or with a regurgitant fraction in excess of 40%, are at high risk of progressing to 
surgical thresholds. This ability to prognosticate may aid decision making for 
clinicians, when mitral valve surgery may be considered in asymptomatic individuals 
with favourable valve morphology. If CMR is to be used for such purposes though, 
future work should include large clinical trials to assess the potential clinical 
benefits. 
In addition to identifying those patients at higher risk of progression to indications 
for intervention, lower levels of MR on CMR quantification had a very low chance 
of progressing within the following few years. The use of these data to rationalise 
follow up and increase efficiency of surveillance may provide significant cost 
savings. Larger studies of patients in this category should be encouraged, in order to 
confirm whether this would be a truly safe approach. The cohort of patients with 
milder degrees of AR in the OxVALVE PCS may provide a useful starting point for 
recruitment, as the majority of the patients have already consented to being contacted 
about relevant future research studies. 
The use of the PISA method for calculating regurgitant volume in MR was compared 
with values derived from CMR imaging in a small sample of patients in the work 
presented here. Although these data suggest a poor correlation, and highlight the 
pitfalls of PISA assessment, this is most likely to reflect the small sample size and 
variety of aetiologies of MR. Non-eccentric jets were common, and these are well 
recognised to be sub-optimal for PISA measurement. The utility of PISA in 
appropriate patients should not be discarded. However, PISA is recommended for 
quantification of MR in international guidelines(33), and these results would suggest 
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that consideration be given to incorporating CMR assessment in to these guidelines, 
particularly when echocardiographic assessment may be suboptimal. Further studies 
should be aimed at larger sample sizes, and also include comparison of newer CMR 
techniques for measuring flow in mitral regurgitation(284, 285) 
6.2 Future areas of study 
The potential areas of future study in VHD are multiple, and span all valve lesions, 
are relevant to a broad cross-section of the population, and involve imaging 
techniques of all modalities, comparisons of timing and type of intervention, 
potential serum biomarkers, and risk factors to aid detection of undiagnosed VHD. 
Some of areas of work were alluded to in chapter 1, and in the discussion sections of 
the relevant chapters; others are discussed below. 
6.2.1 The OxVALVE Population Cohort Study 
The cohort of patients recruited to the OxVALVE PCS provides a potentially rich 
target for future research. The database of echocardiographic and epidemiological 
data can be exploited as it provides a well-characterised population, and blood and 
DNA have also been stored on the majority. The majority of participants have also 
consented to being approached about relevant future studies at enrolment.  
The characteristics of participants with aortic sclerosis within the OxVALVE PCS 
have been interrogated, and linked to imaging studies using CMR. In a separate 
research project, QRISK2 scores in those with and without aortic sclerosis were 
compared. This demonstrated that those with sclerosis had a significantly higher 
QRISK2 score, suggesting that the patients with aortic sclerosis were at a higher 
cardiovascular risk than those without (unpublished data, personal communication). 
This is in keeping with previously published data(48, 286). 
The blood sampling undertaken as part of the OxVALVE PCS may also provide the 
opportunity for important future work. There has been significant interest in the 
utility of serum biomarkers for the prognostication in VHD, particularly the 
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natriuretic peptides(44, 287-289). The potential for natriuretic peptides, in particular 
B-type natriuretic peptide (BNP), to be used as a prognostic marker in VHD and to 
suggest a decline in LV function in these patients has also been demonstrated(44, 45, 
290-293). The OxVALVE PCS offers the potential to combine echocardiographic 
data on valve disease across the spectrum of lesions and severity, with BNP 
measurements obtained at the point of diagnosis, and potentially prospectively. If 
progression of VHD could be tracked with a serum biomarker, the potential to 
identify cut-off levels associated with thresholds for intervention would be greatly 
increased. DNA has been stored on OxVALVE PCS participants, and genetic studies 
of those with VHD may help to increase our understanding of the pathogenesis of 
VHD. An increased understanding at the genetic level may also illuminate new 
targets for potential intervention, in the same way that understanding of the changes 
at the histological level have already triggered research(247). 
Data from the OxVALVE cohort have already contributed to the EchoNoRMAL 
Study(294),  demonstrating the potential for further collaborative work  in VHD in a 
wide range of future research. The possibility for OxVALVE PCS participants to be 
approached about participating in studies of imaging techniques; medical, surgical or 
percutaneous interventions; as well as genetic studies makes this well-characterised 
cohort a valuable research asset in the study of VHD. 
6.2.2 CMR assessment of VHD 
The work presented in chapter 5 highlight the potential for CMR quantitation of MR 
to aid prognostication; this work has now been published(281). There is a real 
clinical question to be answered when looking at the timing of intervention in MR. 
Early intervention for severe asymptomatic MR has been advocated by some(295, 
296), as prognosis may already be reduced by the time that symptoms or adverse 
cardiac features have developed. According to the current guidelines, when severe 
regurgitation is present, the chance of mitral valve repair is considered to be >95%, 
and surgery is performed in a suitably experienced centre with low mortality rates, 
there is a class 2a indication for early surgical intervention(230). The balance of 
surgical risks against poorer outcomes with delayed intervention is a source of 
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significant debate between proponents of a watchful waiting strategy(297), and those 
who would advocate early intervention(298, 299). New methods of risk stratification 
in these patients would therefore be welcomed. Echocardiographic quantitation has 
been demonstrated to be associated with clinical outcomes in medically managed 
patients with MR(12), but this study did not aim to identify patients for surgery. The 
CMR data presented here were targeted at progression to surgery, but larger 
randomised studies would be needed to confirm these findings, and potentially to 
assess clinical benefit of using CMR quantitation for early surgery. Similar outcome 
data using CMR quantification on AR have also been published[203], and these 
findings would also benefit from larger studies to confirm their utility in clinical 
practice.  
Further examples of novel CMR techniques for quantitation in VHD and potential 
markers of clinical outcome also bear consideration. In order to improve CMR 
quantification in the presence of turbulent jets, especially those with high velocities, 
O’Brien et al have used a novel CMR sequence which utilises ultrashort echo 
times(284). The use of this new sequence was associated with lower levels of flow 
error when compared to conventional flow sequences. Mirroring the work done on 
the assessment of left ventricular fibrosis in AS using CMR methods(300), Edwards 
et al looked at the quantification of LV fibrosis in chronic degenerative MR. In a 
small study of 35 patients with MR, they found fibrosis in MR to be associated with 
reduced myocardial deformation and exercise capacity(301). 
6.3 Conclusion 
In conclusion the work presented in this thesis demonstrates the contemporary 
epidemiology of VHD, and refutes the suggestion that attempts to increase detection 
rates may result in unacceptable levels of anxiety. The use of CMR quantification in 
MR can be used to refine prediction of outcome, and PISA quantification in this 
group does correlate well with CMR measures of regurgitant volume. 
Healthcare planning and resource allocation for cardiovascular disease should take 
account of these findings. Adequate investment in provision of care for these patients 
is essential in order to avoid a high burden of heart failure related costs, and a 
  MD Thesis: Joanna d’Arcy 
  137 
degradation in the quality and quantity of life of those with this condition. 
Investment should be targeted on improved methods of assessment and 
prognostication, as well as on increased detection and evidence-based intervention. 
The use of the programmes such as OxVALVE PCS, and focus on newer imaging 
parameters such as those discussed here, need to be linked to outcome studies to 
establish their roles in the optimal pathway of care for those with valvular heart 
disease. 
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